Todd A. Lee, PharmD, PhDweb-prod-2.pharm.uic.edu/webdav/toddlee/pci/TODD A... · Curriculum vitae Revised: January 2018 Todd A. Lee, PharmD, PhD 1. GENERAL INFORMATION A. Personal

Curriculum vitae Revised: January 2018

Todd A. Lee, PharmD, PhD

1. GENERAL INFORMATION

A. Personal Data

Work Address:

Department of Pharmacy Systems, Outcomes and Policy (MC 871)

College of Pharmacy

University of Illinois at Chicago

833 South Wood Street

Chicago, IL, 60612

P: 312-355-5140

F: 312-996-0424

email: [email protected]

skype: todd.a..lee

Citizenship: USA

B. Current Positions

Professor and Interim Head

Department of Pharmacy Systems, Outcomes and Policy

College of Pharmacy


Chicago, IL

C. Education

1997 PharmD Pharmacy College of Pharmacy

Drake University

Des Moines, IA

2001 PhD Pharmaceutical Outcomes Research Department of Pharmacy

Pharmacoeconomics University of Washington

Seattle, WA

D. Licensure

1997 – 2016 Washington State Registered Pharmacist

E. Honors and Awards

1991-1996 Drake University Trustee Scholarship

1995-1997 Iowa Pharmacists Association Scholarship

1996-1997 Iowa Graduate Assistant Scholarship

1997 Award for Excellence in the Prescription Laboratory from Merck and Company

1997-1998 American Foundation for Pharmaceutical Education (AFPE) First Year Graduate

Scholarship

1997-1999 Achievement Rewards for College Scientists (ARCS) Fellowship

1997-1999 Eli Lilly Graduate Fellowship in Pharmaceutical Outcomes

1999 Best Contributed Poster Presentation – Student International Society for

Pharmacoeconomics and Outcomes Research (ISPOR) 4th Annual International Meeting

1999-2001 American Foundation for Pharmaceutical Education (AFPE) – Pre-Doctoral Fellowship

2000 AstraZeneca Managed Care Graduate Fellowship

mailto:[email protected]

Lee TA, Page 2

Revised: January 2018

2003 American Foundation for Pharmaceutical Education (AFPE) Scholar and Fellow

2005 Center Director’s Award, Midwest Center for Health Services and Policy Research

2007 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Bernie J.

O’Brien New Investigator Award

2010-2012 Institute for Health Research and Policy (IHRP) Fellow

2013 Best Reviewers, Pharmacoepidemiology and Drug Safety

F. Academic Appointments

2000 Research Fellow

University of Washington, Seattle, WA

Regence Blue Shield, Seattle, WA

Premera Blue Cross, Mountlake Terrace, WA

2001-2008 Adjunct Assistant Professor

Department of Pharmacy Practice

College of Pharmacy


Chicago, IL

2002-2008 Research Assistant Professor

Institute for Healthcare Studies

Division of General Internal Medicine

Department of Medicine

Northwestern University Feinberg School of Medicine

Chicago, IL

2003-2008 Associate Faculty

Center for Pharmacoeconomic Research

College of Pharmacy


Chicago, IL

2004-2010 Affiliate Assistant Professor

Pharmaceutical Outcomes Research and Policy Program

Department of Pharmacy

University of Washington

Seattle, WA

2004-2008 Lecturer

Department of Preventive Medicine



Chicago, IL

2008-2009 Assistant Professor

Institute for Healthcare Studies

Division of General Internal Medicine



Chicago, IL

2009-2013 Associate Professor

Lee TA, Page 3


Department of Pharmacy Practice

Center for Pharmacoepidemiology and Pharmacoeconomic Research

College of Pharmacy


Chicago, IL

2013-2016 Associate Professor


Center for Pharmacoepidemiology and Pharmacoeconomic Research

College of Pharmacy


Chicago, IL

2010-present Departmental Affiliate

Division of Epidemiology and Biostatistics

School of Public Health


Chicago, IL

2010-present Affiliate Faculty

Division of Pulmonary, Critical Care, Sleep and Allergy



Chicago, IL

2016-present Professor


College of Pharmacy


Chicago, IL

G. Administrative Appointments

2001-2011 Research Scientist, Center for the Management of Complex Chronic Care (CMC3)

Hines VA Hospital, Hines, IL

2007-2008 Director, Northwestern University Health Economic Center, Institute for Healthcare Studies

2007-2011 Director, CMC3 Post-Doctoral Fellowship Program, Hines VA Hospital

2007-2008 Acting Center Co-PI, Center for Management of Complex Chronic Care, Hines VA Hospital

2009-2013 Assistant Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research,

College of Pharmacy, University of Illinois at Chicago

2010-2011 Assistant Director, Center for Management of Complex Chronic Care, Hines VA Hospital

2013-2015 Co-Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research, College

of Pharmacy, University of Illinois at Chicago

2016-present Center Affiliate, Center for Pharmacoepidemiology and Pharmacoeconomic Research,


Lee TA, Page 4


2015-2018 Associate Head for Research, Department of Pharmacy Systems, Outcomes and Policy,


2018-present Interim Head, Department of Pharmacy Systems, Outcomes and Policy, College of

Pharmacy, University of Illinois at Chicago

H. Healthcare Experience

1997-1998 Relief Pharmacist

Swedish Medical Center Home-Care Service

Cameron and Company

Snohomish, WA

1998-1999 Home-Care Pharmacist

Apria Healthcare

Redmond, WA

2. TEACHING

A. Undergraduate or Professional Degree Courses Taught

Pharmacy Law and Ethics, PHARM 543, College of Pharmacy, University of Washington. Teaching

Assistant (4 credit hours). Autumn quarter 1997.

Pharmacotherapeutics I, PHARM 560, College of Pharmacy, University of Washington. Teaching Assistant

(20 lab hours per quarter). Autumn quarter 1997, 1998.

Pharmacotherapeutics II, PHARM 561, College of Pharmacy, University of Washington. Teaching Assistant

(20 lab hours per quarter). Winter quarter 1997, 1998.

Pharmacotherapeutics III, PHARM 562, College of Pharmacy, University of Washington. Teaching Assistant

(20 lab hours per quarter). Spring quarter 1997, 1998.

Pharmacy, Health Care, and Society, PHARM 541, College of Pharmacy, University of Washington. Lecturer

(3 credit hours, 3 lecture hours per quarter). Winter quarter 2000.

Quantitative Methods II, PHARM 479, College of Pharmacy, University of Washington. Teaching Assistant

(3 credit hours, 1.5 lecture hours per quarter, 10 lab discussion hours per quarter). Spring quarter 2001.

Principles of Pharmacoeconomics and Drug Treatment Outcomes, PHAR 356, College of Pharmacy,

University of Illinois at Chicago (2 credit hours, 1 lecture hour 2009, 4 lecture hours 2010). Spring

semester 2009, 2010.

Undergraduate Research, PMPR 380, College of Pharmacy, University of Illinois at Chicago. Instructor

(variable credit hours). Spring 2013.

Roles, Environments, and Communications, PHAR 441, College of Pharmacy, University of Illinois at

Chicago (Course Co-Coordinator, 3 credit hours, 13 lecture hours per semester 2013-2015). Fall semester

2013, 2014, 2015.

Special Projects, PSOP 390, College of Pharmacy, University of Illinois at Chicago. Instructor (variable credit

hours). Fall 2013, 2015.

Lee TA, Page 5


Undergraduate Research, PSOP 380, College of Pharmacy, University of Illinois at Chicago. Instructor

(variable credit hours). Spring semester 2014, Summer term 2017.

Pharmacy and the US Healthcare System, PHAR 461, College of Pharmacy, University of Illinois at Chicago

(Course Co-Coordinator, 2 credit hours). Spring semester 2017

B. Graduate Level Courses Taught

Health Economics and Healthcare Financing, PUB HLTH 433, Department of Preventive Medicine,

Northwestern University Feinberg School of Medicine. Course Coordinator (3 credit hours, 12-15 lecture

hours per quarter). Fall quarter 2004, 2005, 2006, 2007, 2008.

Design of Clinical Trials, BSTT 430, School of Public Health, University of Illinois at Chicago, Instructor

(3 credit hours, 1.5 lecture hours per semester). Spring semester 2003, 2004, 2005.

Advanced Methods and Grant Writing in Health Outcomes Research, PMAD 579, College of Pharmacy,

University of Illinois at Chicago. Instructor (3 credit hours, 6 lecture hours per semester). Spring semester

2006, 2008, 2010.

Pharmacoepidemiology, EPID/PSOP 426, School of Public Health and Department of Pharmacy, Systems,

Outcomes and Policy, University of Illinois at Chicago. Course Coordinator (3 credit hours, 40 lecture

hours per semester). Summer Session I 2010, Spring semester 2013, 2014, 2015, 2016.

Pharmacoepidemiology, PSOP/EPID 526, Department of Pharmacy, Systems, Outcomes and Policy and

School of Public Health, University of Illinois at Chicago. Course Coordinator (3 credit hours, 40 lecture

hours per semester). Spring semester 2017.

Advanced Pharmacoepidemiology Journal Club, PSOP 594, College of Pharmacy, University of Illinois at

Chicago. Course Coordinator (2 credit hours). Fall semester 2015, 2016, 2017; Spring semester 2016,

2017.

PhD Thesis, IPHS 599, School of Public Health, University of Illinois at Chicago. Instructor (variable credit

hours). Fall semester 2011; Spring semester 2012

Independent Study, PSOP 596, College of Pharmacy, University of Illinois at Chicago. Instructor (variable

credit hours). Fall semester 2013, 2014, 2015, 2016, 2017; Spring semester 2013, 2014, 2015, 2016,

2017; Summer term 2015.

Independent Research, PSOP 597, College of Pharmacy, University of Illinois at Chicago. Instructor (variable

credit hours). Spring semester 2014.

PhD Thesis, PSOP 599, College of Pharmacy, University of Illinois at Chicago. Instructor (variable credit

hours). Fall semester 2015, 2016, 2017; Spring semester 2015, 2016, 2017; Summer semester 2015, 2016.

3. PUBLICATIONS

A. Productivity Metrics

H-Index (Scopus)1: 36

Total Citations (Scopus)1: 5873

H-Index (Google Scholar)2: 42

1 From Scopus, last updated June 22, 2017 2 From Google Scholar, last updated August 23, 2017

Lee TA, Page 6


i10-index3: 115

i10-index, since 20123: 98

B. Manuscripts*,†,4

Original Research in Peer-Reviewed Journals

1999

1. Lee TA†, Larson LN. Evaluating the use and the quality of pharmacy drive-up services. J Am Pharm

Assoc. 1999; 39: 338-345. [Cites: 3]

2001

2. Hazlet TK†, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction

software. J Am Pharm Assoc. 2001; 41(2): 200-204. [Cites: 96]

3. Lee TA†, Sullivan SD, Veenstra DL, Ramsey SD, Steger PJK, Malinverni R, Pleil AM, Williamson T.

Economic evaluation of systemic treatments for cytomegalovirus retinitis in AIDS patients.

Pharmacoeconomics. 2001; 19(5 Pt 2): 535-550. [Cites: 8]

2003

4. Lee TA†, Hollingworth W, Sullivan SD. Comparison of directly elicited preferences to preferences

derived from the SF-36 in adult asthmatics. Med Decis Making. 2003; 23(4): 323-334. [Cites: 25]

2004

5. Lee TA†, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive

pulmonary disease. Am J Respir Crit Care Med. 2004; 169(7): 855-859. [Cites: 75]

6. Marceille JR†, Goins JA, Soni R, Biery JC, Lee TA. Chronic heart failure-related interventions in

patients receiving rosiglitazone and insulin. Pharmacotherapy. 2004; 24(10): 1317-1322. [Cites: 18]

7. Lee TA†, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United

States. J Clin Gastroenterol. 2004; 38(10 Suppl 3); S144-S147. [Cites: 36]

2005

8. Lee TA†, Hacek DM, Stroupe KT, Collins SM, Peterson LR. Three surveillance strategies for

vancomycin-resistant enterococci in hospitalized patients: detection of colonization and a cost-

effectiveness model. Infect Control Hosp Epidemiol. 2005; 26(1): 39-46. [Cites: 17]

9. Chiou CF†, Weaver MR, Bell MA, Lee TA, Krieger JW. Development of a multi-attribute pediatric

asthma health outcome measure (PAHOM). Int J Qual Health Care. 2005; 17(1): 23-30. [Cites: 25]

10. Pickard AS†, Wang Z, Walton SM, Lee TA. Are decisions using cost-utility analyses robust to choice

of SF-36/SF-12 preference-based algorithm? Health Qual Life Outcomes. 2005; 3(11). [Cites: 44]

11. Sullivan SD†, Lee TA, Blough DK, Finkelstein JA, Lozano P, Inui TC, Fuhlbrigge AL, Carey VJ,

Wagner E, Weiss KB. A multi-site randomized trial of the effects of physician education and

3 i10-index (number of publications with at least 10 citations) and i10-index since 2012 from Google Scholar, last

updated August 23, 2017 * Denotes trainee, fellow or mentee of Dr. Lee at the time of the publication † Corresponding author 4 Numbers in brackets denote number of citations [cites: ] (from Scopus on June 23, 2017)

Lee TA, Page 7


organizational change in chronic asthma care: Cost-effectiveness analysis of the Pediatric Asthma Care

PORT. Arch Pediatr Adolesc Med. 2005; 159(5): 428-434. [Cites: 45]

12. Buist AS†, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AMB, Crapo RO, Jensen RL,

Burney PGJ. The burden of obstructive lung disease initiative (BOLD): rationale and design. COPD.

2005; 2(2): 277-283. [Cites: 173]

13. Lee TA, Wolozin B†, Weiss KB, Bednar MM. Assessment of the emergence of Alzheimer’s disease

following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J

Alzheimers Dis. 2005; 7(4): 319-324. [Cites: 103]

2006

14. Lee TA†, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest.

2006; 129(6): 1509-1515. [Cites: 80]

15. Valenstein M†, Ganoczy D, McCarthy JF, Kim HM, Lee TA, Blow FC. Antipsychotic adherence over

time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry.

2006; 67(10): 1542-1550. [Cites: 138]

2007

16. Lee TA†, Bartle B, Weiss KB. Impact of NSAIDs on mortality and the effect of pre-existing coronary

artery disease. Am J Med. 2007; 120(1): 98.e9-98.e16. [Cites: 20]

17. Lee TA†, Weaver FM, Weiss KB. The impact of pnuemococcal vaccination on pneumonia rates in

patients with COPD and asthma. J Gen Intern Med. 2007; 22(1): 62-67. [Cites: 44]

18. Lee TA†, Fuhlbrigge AL, Sullivan SD, Finkelstein JA, Inui TS, Lozano P, Weiss KB. Agreement

between caregiver reported healthcare utilization and administrative data for children with asthma. J

Asthma. 2007; 44(3): 189-194. [Cites: 8]

19. Lee TA†, Pickard AS, Bartle B, Weiss KB. Osteoarthritis: a comorbid marker for longer life? Ann

Epidemiol. 2007; 17(5): 380-384. [Cites: 13]

20. Lee TA†, Pickard AS. Meta-analysis of azelastine nasal spray in the treatment of allergic rhinitis.

Pharmacotherapy. 2007; 27(6): 852-859. [Cites: 27]

21. Woltman EM†, Valenstein M, Welsh D, Lee TA, Grabowski J, Reilly PA, Wolschon PA. Using

pharmacy data to inform clinical care: identify partially adherent patients with serious mental illness for

intervention efforts. Psychiatr Serv. 2007; 58(6): 864-867. [Cites: 25]

22. Wolozin B†, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced

incidence of dementia and Parkinson’s disease. BMC Medicine. 2007; 5: 20. [Cites: 199]

23. Buist AS†, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan

SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E for the BOLD

Collaborative Research Group. International variation in the prevalence of chronic obstructive

pulmonary disease: the BOLD study. Lancet. 2007; 370(9589): 741-750. [Cites: 1083]

24. Jordan N†, Lee TA, Valenstein M, Weiss KB. Effect of care setting on evidence-based depression

treatment for veterans with COPD and co-morbid depression. J Gen Intern Med. 2007; 22(10): 1447-

1452. [Cites: 18]

Lee TA, Page 8


25. Joo M*†, Lee TA, Bartle B, Weiss KB. Geographic variation in chronic obstructive pulmonary disease

exacerbation rates. J Gen Intern Med. 2007; 22(11); 1560-1565. [Cites: 17]

26. Stroupe KT†, Smith BM, Lee TA, Tarlov E, Durazo-Arvizu R, Cao L, Nydam T, Huo Z, Burk M,

Cunningham F, Hynes DM, Weiss KB. Effect of increased copayments on pharmacy use in the

Department of Veterans Affairs. Med Care. 2007; 45(11): 1090-1097. [Cites: 17]

27. Lee TA†, Shields AE, Vogeli C, Gibson TB, Sohn MW, Marder WD, Blumenthal D, Weiss KB.

Mortality rates in veterans with multiple chronic conditions. J Gen Intern Med. 2007; 22 Suppl 3: 403-

407. [Cites: 67]

28. Murthy K*†, Grobman WA, Lee TA, Holl JL. Association between rising professional liability

insurance premiums and primary cesarean delivery. Obstet Gynecol. 2007; 110(6): 1264-1269. [Cites:

47]

2008

29. Khare RK*†, Courtney DM, Powell ES, Lee TA. Sixty-four slice computed tomography of the coronary

arteries: cost-effectiveness analysis of patients presenting to the ED with low risk chest pain. Ann

Emerg Med. 2008; 15: 623-632. [Cites: 49]

30. Joo M*†, Lee TA, Weiss KB. Geographic variation in spirometry use in newly diagnosed COPD.

Chest. 2008; 134(1): 38-45. [Cites: 43]

31. Pickard AS†, Wilke CT*, Jung E, Patel S, Lee TA. Use of a preference-based measure of health (EQ-

5D) in COPD and asthma. Resp Med. 2008; 102(4): 519-536. [Cites: 51]

32. Murthy K*†, Grobman WA, Lee TA, Holl JL. Racial disparities in term induction of labor rates in

Illinois. Med Care. 2008; 46(9): 900-904. [Cites: 7]

33. Lee TA†, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for

recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008; 149(6): 380-390.

[Cites: 153]

34. Joo M*†, Lee TA, Bartle B, van de Graaff W, Weiss KB. Patterns of healthcare utilization by COPD

severity: a pilot study. Lung. 2008; 186(5): 307-312. [Cites: 12]

35. Stuck RM†, Sohn MW, Budiman-Mak E, Lee TA, Weiss KB. Charcot arthropathy risk elevation in the

obese diabetic population. Am J Med. 2008; 121: 1008-1014. [Cites: 35]

36. Joo MJ*†, Lee TA, Au DH, Fitzgibbon ML, Weiss KB. Medication use patterns associated with

spirometry in diagnosing COPD. COPD. 2008; 5(6): 360-368. [Cites: 10]

2009

37. Pickard AS†, Jung E, Bartle B, Weiss KB, Lee TA. Coded cause of death and timing of COPD

diagnosis. COPD. 2009; 6(1): 41-47. [Cites: 1]

38. Jordan N†, Lee TA, Valenstein M, Pirraglia PA, Weiss KB. Effect of depression care on outcomes in

COPD patients with depression. Chest. 2009; 135(3): 626-632. [Cites: 16]

39. Jung E, Pickard AS†, Salmon JW, Bartle B, Lee TA. Medication adherence and persistence in the last

year of life in COPD patients. Resp Med. 2009; 103(4): 525-534. [Cites: 27]

Lee TA, Page 9


40. Murthy K*†, Grobman WA, Lee TA, Holl JL. Obstetricians’ rising liability insurance premiums and

inductions at late preterm gestations. Med Care. 2009; 47(4): 425-430. [Cites: 14]

41. Scheetz MH†, Bolon MK, Postelnick M, Noskin GA, Lee TA. Cost effectiveness analysis of an

antimicrobial stewardship team on blood stream infections: a probabilistic analysis. J Antimicrob

Chemother. 2009; 63(4): 816-825. [Cites: 36]

42. Sohn MW†, Lee TA, Stuck RM, Frykberg R, Budiman-Mak E. Mortality risk of Charcot arthropathy

compared to diabetic foot ulcer and diabetes alone. Diab Care. 2009; 32(5): 816-821. [Cites: 50]

43. Lee TA†, Wilke CT*, Joo M*, Stroupe KT, Krishnan J, Schumock GT, Pickard AS. Outcomes

associated with tiotropium use in COPD patients. Arch Intern Med. 2009; 169(15): 1403-1410. [Cites:

39]

44. Lee TA†, Pickard AS, Bartle B, Schumock GT. Mortality risk in patients receiving drug regimens with

theophylline for chronic obstructive pulmonary disease. Pharmacotherapy. 2009; 29(9): 1039-1053.

[Cites: 20]

45. Gibson TB†, Lee TA, Vogeli CS, Hidalgo J, Carls GS, Sredl K, DesHarnais S, Marder WD, Weiss KB,

Williams TV, Shields AE. A four-system comparison of patients with chronic illness: the Military

Health System, Veterans Health Administration, Medicaid, and commercial plans. Mil Med. 2009;

174(9): 936-943. [Cites: 12]

46. Pickard AS†, Shaw JW, Lin HW, Trask P, Aaronson N, Lee TA, Cella D. A patient-based utility

measure of health for clinical trials of cancer therapy based on the European Organization for the

Research and Treatment of Cancer Quality of Life Questionnaire. Value Health. 2009; 12(6): 977-988.

[Cites: 17]

47. Nielsen R†, Johannessen A, Benediktsdottir B, Gislason T, Buist AS, Gulsvik A, Sullivan SD, Lee TA.

Present and future costs of COPD in Iceland and Norway: Results from the BOLD study. Eur Respir J.

2009; 34(4): 850-857. [Cites: 57]

48. Braddy KK†, Imam, SN, Palla KR, Lee TA. Vitamin D deficiency/insufficiency practice patterns in a

Veterans Administration long-term care population: a retrospective analysis. J Am Med Dir Assoc.

2009; 10(9): 653-657. [Cites: 47]

2010

49. Wilke CT*, Pickard AS†, Walton SM, Moock J, Kohlman T, Lee TA. Statistical implications of utility

weighted and equally weighted HRQL measures: an empirical study. Health Econ. 2010; 19(1): 101-

110. [Cites: 7]

50. Sohn MW†, Stuck RM, Pinzur M, Lee TA, Budiman-Mak E. Lower extremity amputation risk

following Charcot arthropathy and diabetic foot ulcer. Diab Care. 2010; 33(1): 98-100. [Cites: 68]

51. Ogale SS*, Lee TA†, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with

ipratropium bromide in COPD. Chest. 2010; 137(1): 13-19. [Cites: 49]

52. Joo MJ*†, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly

diagnosed COPD. Respir Med. 2010; 104(2): 246-252. [Cites: 38]

Lee TA, Page 10


53. Evans CT†, Li K, Burns SP, Smith B, Lee TA, Weaver FM. Antibiotic prescribing for acute respiratory

infection and subsequent outpatient and hospital utilization in veterans with spinal cord injury and

disorder. PM& R. 2010; 2(2): 101-109. [Cites: 5]

54. Hynes D†, Tarlov E, Durazo-Arvizu R, Perrin R, Zhang Q, Weichle T, Ferriera M, Lee TA, Benson A,

Bhoopalam N, Bennett C. Surgery and adjuvant chemotherapy use among veterans with colon cancer:

insights from a California study. J Clin Oncol. 2010; 28(15): 2571-2576. [Cites: 8]

55. Stein BD, Charbeneau JT, Lee TA, Schumock GT, Lindenauer PK, Bautista A, Naureckas ET,

Krishnan JA†. Hospitalizations for acute exacerbations of chronic obstructive pulmonary disease: how

you count matters. COPD. 2010; 7(3): 164-171. [Cites: 20]

56. Brennan NJ, Lee TA†, Wilk AS, Lyttle CS, Weiss KB. Defining an episode of care for colonoscopy:

work of the high value health care project characterizing episodes and costs of care. Gastrointest

Endosc Clin N Am. 2010; 20(4): 735-750. [Cites: 1]

57. Sohn MW†, Budiman-Mak E. Stuck RM, Siddiqui F, Lee TA. Diagnostic accuracy of existing methods

for identifying diabetic foot ulcers from inpatient and outpatient datasets. J Foot Ankle Res. 2010; 3:

27. [Cites: 11]

58. Lee TA†, Chang CL, Stephenson JJ, Sajjan SG, Maiese EM, Everett S, Allen-Ramey F. Impact of

asthma controller medications on medical and economic resource utilization in adult asthma patients.

Curr Med Res Opin. 2010; 26(12): 2851-2860. [Cites: 11]

2011

59. Cooke CR†, Joo MJ*, Anderson SM, Lee TA, Udris EM, Johnson E, Au DH. The validity of using

ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease.

BMC Health Serv Res. 2011; 11:37. [Cites: 44]

60. Schumock GT†, Walton SM, Lee TA, Marx SE, Audhya P, Andress DL. Comparative effectiveness of

paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

Nephron Clin Pract. 2011; 117(2): c151-c159. [Cites: 6]

61. Pickard AS†, Yang Y, Lee TA. Comparison of health-related quality of life measures in chronic

obstructive pulmonary disease. Health Qual Life Outcomes. 2011; 9(1): 26. [Cites: 46]

62. Sohn MW†, Budiman-Mak E, Lee TA, Oh E, Stuck RM. Significant J-shaped association between

body mass index (BMI) and diabetic foot ulcers. Diabetes Metab Res Rev. 2011; 27(4): 402-409.

[Cites: 14]

63. Murthy K*†, Grobman WA, Lee TA, Holl JL. Trends in induction of labor at early-term gestation. Am J

Obstet Gynecol. 2011; 204(5): 435.e1-36. [Cites: 22]

64. Morden NE†, Sullivan SD, Bartle B, Lee TA. Skeletal health in men with chronic lung disease: rates of

testing, treatment and fractures. Osteoporos Int. 2011; 22(6): 1855-1862. [Cites: 11]

65. Schumock GT†, Lee TA, Joo MJ*, Valuck RJ, Stayner LT, Gibbons RD. Association between

leukotriene-modifying agents and suicide: what is the evidence? Drug Safety. 2011; 34(7): 533-544.

[Cites: 18]

Lee TA, Page 11


66. Scheetz MH†, Bolon MK, Esterly JS, Reddy P, Postelnick M, Lee TA. Life-years gained with

meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results

of a probabilistic model. Pharmacotherapy. 2011; 31(5): 469-479. [Cites: 1]

67. Schumock GT†, Gibbons RD, Lee TA, Joo MJ*, Valuck RJ, Stayner LT. Relationship between

leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US.

Drug Healthc Patient Saf. 2011; 3: 47-57. [Cites: 8]

68. Murthy K*†, Holl JL, Lee TA, Grobman WA. National trends and racial differences in late preterm

induction. Am J Obstet Gynecol. 2011; 205(5): 458.e1-7. [Cites: 9]

69. Joo MJ*†, Au DH, Fitzgibbon ML, McKell J, Lee TL. Determinants of spirometry use and accuracy of

COPD diagnosis in primary care. J Gen Intern Med. 2011; 26(11): 1272-1277. [Cites: 21]

70. Pickard AS†, Lee TA, Solem CT*, Joo MJ*, Schumock GT, Krishnan JA. Prioritizing comparative-

effectiveness research topics via stakeholder involvement: an application in COPD. Clin Pharmacol

Ther. 2011; 90(6): 888-892. [Cites: 8]

71. Valenstein M†, Kavanagh J, Lee TA, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis D,

Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC. Using a pharmacy-

based intervention to improve antipsychotic adherence among patients with serious mental illness.

Schizophr Bull. 2011; 37(4): 727-736. [Cites: 37]

2012

72. Schumock GT†, Gibbons RD, Lee TA, Joo MJ*, Stayner LT, Valuck RJ. The association between

leukotriene-modifying agents and spontaneously reported suicide. Drug Information Journal. 2012;

46(1): 99-106. [Cites: 2]

73. Stein BD, Bautista A, Schumock GT, Lee TA, Charbeneau JT, Lauderdale DS, Naureckas ET, Meltzer

DO, Krishnan JA†. The validity of ICD-9-CM diagnosis codes for identifying patients hospitalized for

COPD exacerbations. Chest. 2012; 141(1): 87-93. [Cites: 47]

74. Solem CT*, Lee TA, Joo MJ*, Lambert BL, Walton SM, Pickard AS†. Complexity of medication use in

newly diagnosed COPD patients. Am J Geriatr Pharmacother. 2012; 10(2): 110-122. [Cites: 8]

75. Santayana EM, Grim SA, Janda WM, Layden JE, Lee TA, Clark NM. Risk factors and outcomes

associated with vancomycin-resistant Enterococcus (VRE) infections with reduced susceptibility to

linezolid. Diagn Microbiol Infect Dis. 2012; 74(1): 39-42. [Cites: 8]

76. Schumock GT†, Stayner LT, Valuck RJ, Joo MJ*, Gibbons RD, Lee TA. Risk of suicide attempt in

asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control

study. J Allergy Clin Immunol. 2012; 130(2): 368-375. [Cites: 17]

77. Tarlov E†, Stroupe KT, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM,

Hynes DM. Trends in anemia management in lung and colon cancer patients in the US Department of

Veterans Affairs, 2002-2008. Support Care Cancer. 2012; 20(8): 1649-1657. [Cites: 6]

78. Patterson BW†, Khare RK*, Courtney M, Lee TA, Kyriacou DN. Cost-effectiveness of influenza

vaccination of older adults in the emergency department setting. Am J Emerg Med. 2012; 30(7): 1072-

1079. [Cites: 4]

Lee TA, Page 12


79. Stroupe KT†, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM,

Hynes DM. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in cancer patients

following FDA policy change. Pharamcotherapy. 2012; 32(11): 988-997. [Cites: 3]

80. Tarlov E†, Lee TA, Weichle TW, Durazo-Arvizu R, Zhang Q, Perrin R, Bentrem D, Hynes DM.

Reduced overall and event-free survival among colon cancer patients using dual system care. Cancer

Epidemiol Biomarkers Prev. 2012; 21(12): 2231-2241. [Cites: 9]

81. Schnell K, Weiss CO, Lee TA, Krishnan JA, Leff B, Wolff JL, Boyd C. The prevalence of clinically-

relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using

data from NHANES 1999-2008. BMC Pulm Med. 2012; 12:26. [Cites: 86]

2013

82. Krishnan JA, Lindenauer PK, Au DH, Carson SS, Lee TA, McBurnie MA, Naureckas ET, Vollmer

WM, Mularski RA. Stakeholder priorities for comparative effectiveness research in COPD: a workshop

report. Am J Respir Crit Care Med. 2013; 187(3): 320-326. [Cites: 20]

83. Joo MJ†, Sharp LK, Au DH, Lee TA, Fitzgibbon ML. Use of spirometry in the diagnosis of COPD: a

qualitative study in primary care. COPD. 2013; 10(4): 444-449. [Cites: 11]

84. Stroupe KT†, Smith BM, Hogan TP, St. Andre JR, Gellad WF, Weiner S, Lee TA, Burk M,

Cunningham F, Piette JD, Rogers TJ, Huo Z, Weaver FM. Medication acquisition across systems of

care and patient-provider communication among older veterans. Am J Health-Syst Pharm. 2013; 70:

804-813. [Cites: 7]

85. Brahmbhatt M, Palla K, Kossifologos A, Mitchell D, Lee T. Appropriateness of medication prescribing

using the STOPP/START criteria in veterans receiving home-based primary care. Consult Pharm.

2013; 28(6): 361-369. [Cites: 3]

86. Carbone LD†, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig HM, Akhigbe T, Weaver FM. The

association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord

Med. 2013; 36(2): 91-96. [Cites: 8]

87. Lindenauer PK†, Grosso LM, Wang C, Wang Y, Krishnan JK, Lee TA, Au DH, Mularski RA,

Bernheim SM, Drye EE. Development, validation and results of a risk-standardized measure of hospital

30-day mortality for patients with exacerbation of COPD. J Hosp Med. 2013; 8: 428-435. [Cites: 6]

88. Carbone L, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig H, Akhigbe T, Thomas F, Bailey L,

Weaver F. The association of anticonvulsant use with fractures in spinal cord injury. Am J Phys Med

Rehabil. 2013; 92(12): 1037-1046. [Cites: 4]

89. Sohn MW†, Meadows JL, Oh EH, Budiman-Mak E, Lee TA, Stone NJ, Pearce WB. Statin use and

lower-extremity amputation risk in non-elderly diabetic patients. J Vasc Surg. 2013; 58(6): 1578-1585.

[Cites: 11]

90. Lin FJ*, Lee TA, Wong PS, Pickard AS†. Evaluation of changes in guidelines for medication

management of stable chronic obstructive pulmonary disease. J Eval Clin Pract. 2013; 19(5): 953-960.

[Cites: 2]

2014

Lee TA, Page 13


91. Jordan N†, Sohn MW, Bartle B, Valenstein M, Lee Y, Lee TA. Association between chronic illness

complexity and receipt of evidence-based depression care. Med Care. 2014; 52 Suppl 3: S126-S131.

[Cites: 3]

92. Sumino K*, O’Brian K, Bartle B, Au DH, Castro M, Lee TA. Coexisting chronic conditions associated

with mortality and morbidity in adult patients with asthma. J Asthma. 2014; 51(3): 306-314. [Cites: 17]

93. Suda KJ, Regen SM, Lee TA, Easterling JL, Hunklwer RJ, Danziger LH. Outpatient influenza antiviral

prescription trends with influenza-like illness in the USA, 2008-2010. Int J Antimicrob Agents. 2014;

43(3): 279-283. [Cites: 2]

94. Dilokthornsakul P*, Chaiyakunapruk N, Schumock GT, Lee TA†. Calendar time-specific propensity

score analysis for observational data: a case study estimating the effectiveness of inhaled long-acting

beta-agonist on asthma exacerbations. Pharmacoepidemiol Drug Safety. 2014; 23(2): 152-164. [Cites:

3]

95. Adimadhyam S*, Schumock GT, Walton S, Joo M, McKell J*, Lee TA†. Risk of arrhythmias associated

with ipratropium bromide in children, adolescents and young adults with asthma: a nested case-control

study. Pharmacotherapy. 2014; 34(4): 315-323. [Cites: 2]

96. Carbone L†, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig HM, Bailey L, Weaver FM. Thiazide

use is associated with reduced risk for incident lower extremity fractures in men with spinal cord

injury. Am J Phys Med Rehabil. 2014; 95(6): 1015-1020. [Cites: 2]

97. Garg N, Rolle AJ, Lee TA, Prasad B*. Home-based diagnosis of obstructive sleep apnea in an urban

population. J Clin Sleep Med. 2014; 10(8): 879-885. [Cites: 9]

98. Lin FJ*, Pickard AS, Krishnan JK, Joo MJ, Au DH, Carson SS, Gillespie S, Henderson AG, Lindenauer

PK, McBurnie MA, Mularski RA, Naurekas ET, Vollmer WM, Lee TA; CONCERT Consortium.

Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-

5D-5L and PROMIS-43 short form. BMC Med Res Methodol. 2014; 14:78. [Cites: 12]

99. Cannon J, Lee TA, Clark N, Setlak P, Grim S. The risk of seizures among the carbapenems: a meta-

analysis. J Antimicrob Chemother. 2014; 69(8): 2043-2055. [Cites: 21]

100. Prentice JC, Conlin PR, Gellad WF, Edelman D, Lee TA, Pizer SD. Capitalizing on prescribing pattern

variation to compare medications for type 2 diabetes. Value Health 2014; 17(8): 854-862. [Cites: 10]

101. Dilokthornsakul P*, Chaiyakunapruk N, Nimpitakpong P, Jeanperrapong N, Jampachaisri K, Lee TA.

Understanding medication oversupply and its predictors in the outpatient departments in Thailand.

BMC Health Serv Res 2014; 14:408. [Cites: 1]

102. Prieto-Centurion V, Rolle AJ, Au DH, Carson SS, Henderson AG, Lee TA, Lindenauer PK, McBurnie

MA, Mularski RA, Naureckas ET, Vollmer WM, Joese BJ, Krishnan JA, CONCERT Consortium.

Multicenter study comparing case definitions used to identify patients with chronic obstructive

pulmonary disease. Am J Respir Crit Care Med 2014; 190(9): 989-995. [Cites: 12]

103. Zueger PM*, Schultz NM, Lee TA. Cost effectiveness of liraglutide in type II diabetes: a systematic

review. Pharmacoeconomics. 2014; 32(11): 1079-1091. [Cites: 5]

104. Lee WJ, Lee TA, Pickard AS, Caskey RN, Schumock GT†. Drugs associated with adverse events in

children and adolescents. Pharmacotherapy. 2014; 34(9): 918-926. [Cites: 7]

Lee TA, Page 14


105. Qato DM†, Daviglus ML, Wilder J, Lee T, Qato D, Lambert B. ‘Pharmacy deserts’ are prevalent in

Chicago’s predominantly minority communities, raising medication access concerns. Health Aff

(Millwood); 2014; 33(11): 1958-1965. [Cites: 3]

106. Patel UC†, McKissic EL, Kasper D, Lentino JR, Pachucki CT, Lee T, Lopansri BK. Outcomes of

ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus

(MSSA) bloodstream infections. Int J Clin Pharm. 2014; 36(6): 1282-1289. [Cites: 1]

2015

107. Ursan ID, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS†. Emergence of BCR-ABL kinase domain

mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials

of tyrosine kinase inhibitors. J Manag Care Spec Pharm. 2015; 21(2): 114-122. [Cites: 6]

108. Prentice JC, Conlin PR, Gellad WF, Edelman D, Lee TA, Pizer SD. Long-term outcomes of analogue

insulin compared with NPH for patients with type 2 diabetes mellitus. Am J Manag Care. 2015; 21(3):

e235-e243. [Cites: 0]

109. Lee WJ, Lee TA, Pickard AS, Shoaibi A, Schumock GT†. Using linked electronic data to validate

algorithms for health outcomes in administrative databases. J Comp Eff Res. 2015; 4(4): 359-366.

110. Qato DM†, Manzoor BS, Lee TA. Drug-alcohol interactions in older U.S. adults. J Am Geriatr Soc.

2015; 63(11): 2324-2331

2016

111. Stanford RH†, Nag A, Mapel DW, Lee TA, Rosiello R, Vekeman F, Gauthier-Loiselle M, Duh MS,

Merrigan JF, Schatz M. Validation of a new risk measure for chronic obstructive pulmonary disease

exacerbation using health insurance claims data. Ann Am Thorac Soc. 2016; 13(7): 1067-1075.

112. Qato DM†, Lee TA, Durazo-Arvizu R, Wu D, Wilder J, Reina SA, Cai J, Gonzalez F 2nd, Talavera

GA, Ostfeld RJ, Daviglus ML. Statin and aspirin use among Hispanic and Latino adults at high risk for

cardiovascular risk: findings from the Hispanic Community Health Study/Study of Latinos. J Am Heart

Assoc. 2016; 5(4): pii: e002905. [Cites: 1]

113. Fishbein AB†, Lee TA, Oh SS, Eng C, Hu D, Huntsman S, Farber HJ, Serebrisky D, Silverbery J,

Williams LK, Seibold MA, Sen S, Borrell LN, Avila P, Rodriguez-Cintron W, Rodriguez-Santana JR,

Burchard EG, Kumar R. Sensitization to mouse and cockroach allergens and asthma morbidity in urban

minority youth. Genes-environments and admixture in Latino American (GALA-II) and Study of

African-Americans, Asthma, Genes and Environments (SAGE-II). Ann Allergy Asthma Immunol.

2016; 117(1): 43-49. [Cites: 1]

114. Lee WJ, Briars L, Lee TA, Calip GS, Suda KJ, Schumock GT†. Top-down versus step-up prescribing

strategies for tumor necrosis factor alpha inhibitors in children and young adults with inflammatory

bowel disease. Inflamm Bowel Dis. 2016; 22(10): 2410-2417.

115. Dilokthornsakul P*†, Lee TA, Dhippayom T, Jeanpeerapong N, Chaiyakunapruk N. Comparison of

health care utilization and costs for patients with asthma by severity and health insurance in Thailand.

Value Health Reg Issues. 2016; 9: 105-111. [Cites: 2]

116. Lee WJ, Briars L, Lee TA, Calip GS, Suda KJ, Schumock GT†. Use of tumor necrosis factor-alpha

inhibitors in children and young adults with juvenile idiopathic arthritis or rheumatoid arthritis.

Pharmacotherapy. 2016; 36(12): 1201-1209.

Lee TA, Page 15


2017

117. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati, AK, Walton SM†. Contemporary trends in

oral antiplatelet use in patients treated with percutaneous coronary intervention for acute coronary

syndrome. J Manag Care Spec Pharm. 2017; 23(1): 57-63. [Cites: 2]

118. Samp JC*, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA†. Comparative effectiveness of long-

acting β2-agonists combined with a long-acting muscarinic antagonist or inhaled corticosteroid in

chronic obstructive pulmonary disease. Pharmacotherapy. 2017; 37(4): 447-455.

119. Jiang R, Lee I*, Lee TA, Pickard AS†. The societal costs of heroin use disorder in the United States.

PLos One. 2017; 12(5): e0177323.

120. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM†. Comparative effectiveness

of oral antiplatelet agents in patients with acute coronary syndrome. Pharmacotherapy. 2017; 37(8):

877-887.

121. Pickard AS†, Hung YT, Lin FJ, Lee TA. Patient experience-based value sets: are they stable? Med

Care. 2017; 55(11): 979-984.

122. Manzoor BS, Lee TA, Sharp L, Walton SM, Galanter WL, Nutescu EA†. Real-world adherence and

persistence with direct oral anticoagulants in adults with atrial fibrillation. Pharmacotherapy. 2017;

37(10): 1221-1230.

123. Samp JC*, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA†. Risk of cardiovascular and

cerebrovascular events in COPD patients treated with long-acting β2-agonist combined with a long-

acting muscarinic or inhaled corticosteroid. Ann Pharmacother. 2017; 51(11): 945-953.

124. Manzoor BS, Walton SM, Sharp LK, Galanter WL, Lee TA, Nutescu EA. High number of newly

initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. J Thromb

Thrombolysis. 2017; 44(4): 435-441.

125. Xing S*†, Lee TA. Increased risk of diabetes among 6-24 years olds using second generation

antipsychotics. J Child Adolesc Psychopharmacol. 2017; 27(9): 782-791.

In Press

126. Lee WJ, Lee TA, Suda KJ, Calip GS, Briars LA, Schumock GT†. Risk of serious bacterial infection

associated with tumor necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.

Rheumatology. In Press.

127. Harrington RL*, Adimadhyam S, Lee TA, Schumock GT, Antoon JW†. Oseltamivir and suicide among

pediatric patients. Ann Fam Med. In Press.

128. Samp JC*, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA†. Predicting acute exacerbations in

chronic obstructive pulmonary disease. J Manag Care Pharm. In Press.

129. Lee WJ, Lee TA, Suda KJ, Calip GS, Briars LA, Schumock GT†. Risk of serious bacterial infection

associated with tumor necrosis factor-alpha inhibitors in children and young adults with inflammatory

bowel disease. Inflamm Bowel Dis. In Press.

Lee TA, Page 16


130. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardata AK, Walton SM†. Comparison of six-month

costs between oral antiplatelet agents following acute coronary syndrome. J Manag Care Spec Pharm.

In Press.

131. Xing S*, Kim S, Schumock GT, Touchette DR, Calip GS, Loew A, Lee TA†. Risk of diabetes

hospitalization or diabetes drug intensification in patients with depression and diabetes using second

generation antipsychotics compared to other depression therapies. Prim Care Companion CNS Disord.

In Press.

132. Xing S*, Calip GS, Leow AD, Kim S, Schumock GT, Touchette DR, Lee TA†. The impact of

depression medications on oral antidiabetic drug adherence in patients with diabetes and depression. J

Diabetes Complications. In Press.

Review or Non-original Research Articles in Peer-Reviewed Journals

133. Sullivan SD†, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000; 117: 5S-9S. [Cites:

411]

134. Lee TA†, Weiss KB. An update on the health economics of asthma and allergy. Curr Opin Allergy Clin

Immunol. 2002; 2: 195-200. [Cites: 8]

135. Lee TA†, Drivers CH, Leibman CW. Evaluating the efficiency of treatment in the allergic rhinitis

market. J Manag Care Pharm. 2004 Jan-Feb; 10(1 Suppl 1): 3-8. [Cites: 5]

136. Reed SD†, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the

literature. Pharmacoeconomics. 2004; 22(6): 345-361. [Cites: 151]

137. Cannon JP†, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: A retrospective

review of over 200 cases. Eur J Clin Microbiol Infect Dis. 2005; 24(1): 31-40. [Cites: 218]

138. Chapman KR†, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemel A, Lee

TA, Miravitlles M, Aldington S, Beasly R. Epidemiology and costs of chronic obstructive pulmonary

disease. Eur Respir J. 2006; 27(1): 188-207. [Cites: 431]

139. Vogeli C†, Shields A, Lee TA, Gibson TB, Marder WD, Weiss KB, Blumenthal D. Multiple chronic

conditions: Prevalence and implications for patient management, outcomes and costs. J Gen Intern

Med. 2007; 22 Suppl 3: 391-395. [Cites: 373]

140. Joo MJ*†, Au DH, Lee TA. Use of spirometry in the diagnosis of COPD and efforts to improve quality

of care. Transl Res. 2009; 154(3): 103-110. [Cites: 13]

141. Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, Smith RA. Asthma

outcomes: Healthcare utilization and costs. J Allergy Clin Immunol. 2012; 129(3 Suppl): S49-S64.

[Cites: 42]

142. Mularski RA, McBurnie MA, Lindenauer PK, Lee TA, Vollmer WM, Au DH, Carson SS, Krishnan

JA. Comparative effectiveness research in chronic obstructive pulmonary disease. J Comp Eff Res.

2012; 1(1): 71-82. [Cites: 5]

143. Lee TA, von Riedemann S, Tricta F. Cost-utility of chelators in transfuction-dependent beta-

thalassemia major patients: a review of the pharmacoeconomic literature. Expert Rev Pharmacoecon

Outcomes Res. 2014; 4(5): 651-660. [Cites: 1]

Lee TA, Page 17


144. Lee TA. Devices made easy: a review of inhaler technique and patient adherence in COPD. Pharmacy

Times. 2015; 81(6). [Cites: 0]

145. Han MLK, Martinez CH, Au DH, Bourbeau J, Boyd CM, Branson R, Criner GJ, Kalhan R, Kallstrom

TJ, King A, Krishnan JA, Lareau SC, Lee TA, Lindell K, Mannino DM, Martinez FJ, Meldrum C,

Press VG, Thomashow B, Tycon L, Sullivan JL, Walsh J, Wilson KC, Wright J, Yawn B, Zueger PM*,

Bhatt SP, Dransfield MT. Meeting the challenges of COPD care delivery in the USA: a multiprovider

perspective. Lancet Respir Med. 2016; 4(6): 473-526. [Cites: 5]

146. Donnelly PC, Sutich R, Easton R, Adejumo O, Lee TA, Logan LK. Ceftriaxone-associated biliary and

cardiopulmonary adverse events in neonates: a systematic review of the literature. Pediatr Drugs.

2017; 19(1): 21-34. [Cites: 2]

147. Law EH, Badowski M, Hung YT, Weems K, Sanchez A, Lee TA. Association between proton pump

inhibitors and microscopic colitis: implications for practice and future research. Ann Pharmacother.

2017; 51(3): 253-263.

Articles in Non-Refereed Journals

148. Lee TA†, Weiss KB. Preference assessment in patients with asthma. Expert Rev Pharmacoeconomics

Outcomes Res. 2002; 2(6): 607-618. [Cites: 4]

149. Rutten-van Mölken M†, Lee TA. Economic modeling in COPD. Proc Am Thorac Soc. 2006; 3(7): 630-

634. [Cites: 24]

C. Letters to the Editor

1. Lee TA, Weiss KB. Inhaled corticosteroids and fracture risk in COPD [letter]. Am J Respir Crit Care

Med. 2004; 170(1): 94-95.

2. Lee TA, Sullivan SD, Weiss KB. Cost-effectiveness of inhaled corticosteroids in COPD [letter]. Am J

Med. 2004; 117(8): 618.

3. Bendar MM, Lee TA, Wolozin B, Weiss KB. Coronary artery bypass grafting is not a risk factor for

dementia or Alzheimer’s disease [letter]. Neurology. 2006; 66(11): 1785.

4. Lee TA, Pickard AS, Au DH. How much did biases in study of chronic obstructive pulmonary disease

medications and mortality affect the outcome [letter]. Ann Intern Med. 2009; 150(6): 426-427.

5. Ogale S, Lee TA, Sullivan SD. Safety of ipratropium bromide [letter]. Chest. 2010; 138(1): 235-236.

6. Sohn MW, Oh EH, Budiman-Mak E, Lee TA, Stone NJ, Pearce WB. Reply [letter]. J Vasc Surg. 2014;

59(3): 876.

7. Law EH, Badowski M, Lee TA. Reply: Association between proton pump inhibitors and microscopic

colitis: implications for practice and future research [letter]. Ann Pharmacother. 2017; 51(8): 719.

D. Dissertation

Lee TA. Comparison of the cost-effectiveness of triamcinolone acetonide (Azmacort HFA) and

fluticasone propionate (Flovent) in adult asthmatics in a randomized controlled equivalence trial.

University of Washington. 2001. Pgs 154. UMI Publication No. AAT 3022859. ISBN 0-493-33719-9.

E. Book Chapters

Lee TA, Page 18


1. Ramsey SD, Lee TA, Sullivan SD. Financial aspects of emphysema and LVRS. In: Lung Volume

Reduction Surgery for Emphysema. Eds. Fessler HE, Reilly JJ, Sugarbaker DJ. New York: Marcel

Dekker; 2003. Pgs. 413-424.

2. Bennett CL, Lee TA. Economic analysis of cancer treatment. In: Clinical Oncology. Eds. Abeloff MD,

Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Churchill Livingstone; 2004.

3. Sullivan SD, Lee TA, Ogale S. Socioeconomic burden of COPD. In: Long-Term Intervention in

Chronic Obstructive Pulmonary Disease. Eds. Pauwels R, Postma D, Weiss S. Marcel Dekker, Inc.;

2004. Pgs 101-118.

4. Lee TA. Socioeconomic burden of acute asthma exacerbations. In: Exacerbations of Asthma. Eds.

O’Byrne P, Johnston S. Taylor and Francis. 2006. Pgs. 43-56.

5. Lee TA, Pickard AS. Exposure definition and measurement. In: Velentgas P, Dreyer NA, Nourjah P, et

al., eds. Developing a Protocol for Observational Comparative Effectiveness Research: A User’s

Guide. AHRQ Publication No. 12(13)-EHC099. Rockville, MD: Agency for Healthcare Research and

Quality; January 2013: Chapter 4, pp. 45-58

F. Federal Reports / Commissioned Reports 1. Lee TA, Schumock GT, Bartle B, Pickard AS. Mortality risk in chronic obstructive pulmonary disease

patients using theophylline. Effective Health Care Research Report No. 16. (Prepared by Chicago-Area

DEcIDE Center Under Contract No. HHSA29020050038I TO1). Rockville, MD: Agency for

Healthcare Research and Quality December 2009. Available at:

http://effectivehealthcare.ahrq.gov/reports/final.cfm.

2. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS. Outcomes associated

with tiotropium use in chronic obstructive pulmonary disease patients. Effective Health Care Research

Report No. 15. (Prepared by Chicago-Area DEcIDE Center Under Contract No. HHSA29020050038I

TO4). Rockville, MD: Agency for Healthcare Research and Quality. December 2009. Available at:

http://effectivehealthcare.ahrq.gov/reports/final.cfm.

3. Schumock GT, Lee TA, Pickard AS, Lee WJ, Patel H, Dilokthornsakul P, Shoaibi A, Archdeacon P.

Alternative methods for health outcomes of interest validation. Silver Spring, MD: Food and Drug

Administration, Sentinel Initiative, Mini-Sentinel Program. Available at

http://www.minisentinel.org/methods/outcome_validation/details.aspx?ID=105. Published August 31,

2013. Last accessed September 25, 2013.

4. INVITED PRESENTATIONS

A. Contributed Workshops, Training Courses, Symposia

1. Lee TA, Hollingworth W, Kind P. “Can the SF-36 be used in calculating QALYs?” Contributed

Workshop Presentation, International Society for Pharmacoeconomics and Outcomes Research, 8th

Annual International Meeting, Crystal City, VA, May 2003.

2. Sullivan SD, Lee TA. “Evaluating clinical and economic evidence for drug purchasing and formulary

considerations.” VA Medication Advisory Panel Committee Meeting, Chicago, IL, September 2004.

3. Buist AS, Padila RP, Menezes AM, Vollmer W, Lee TA, Burney P. “Measuring COPD prevalence:

two models for international collaboration.” 2005 ATS International Conference, San Diego, CA, May

2005.

http://effectivehealthcare.ahrq.gov/reports/final.cfm

http://effectivehealthcare.ahrq.gov/reports/final.cfm

http://www.minisentinel.org/methods/outcome_validation/details.aspx?ID=105

Lee TA, Page 19


4. Sullivan SD, Lee TA. “VA PBM/MAP pharmacoeconomic training program.” VA Pharmacy Benefits

Management Annual Meeting, Washington, DC, September 2005.

5. Buist S, Lee TA, Fabbri L, Jones P. “New Insights into the worldwide burden of COPD.” 2006

European Respiratory Society Congress, Munich, Germany, September 2006.

6. Au D, Doherty DE, Enright PL, Jones PW, Buist AS, Diette GB, Lee TA. “COPD Detection and Basis

for Treatment.” 2007 American Thoracic Society International Conference, San Francisco, CA, May

2007.

7. Bosworth H, Kiefe C, Lee TA, Weinberger M. “Managing Complexity in Chronic Care within the

Largest Integrated Health System in the U.S.: Current and Future Directions.” AcademyHealth Annual

Research Meeting 2007, Orlando, FL, June 2007.

8. Lee TA, Gaind S. “Complexity measurement in psychiatric care: a model for reimbursement.”

Canadian Psychiatric Association, Ottawa, ON, Canada, April 2008.

9. Enright PL, Tashkin DP, Lee TA, Furberg CD, Barr RG. “Are heart attacks a side effect of

anticholinergic inhalers?” CHEST 2008 International Meeting, Philadelphia, PA, October 2008.

10. Upson DJ, Lee TA. “Medication availability and access: issues of value and affordability.” 2009

American Thoracic Society International Conference, San Diego, CA, May 2009.

11. Busse WW, Reddel HK, Krishnan JA, Peden D, Wise RA, Cloutier M, Wilson SR, Lee TA, Wenzel

SE. “NHLBI and NAIAD Recommendations for Standardized Asthma Outcomes in Clinical

Research.” Scientific Symposium, 2011 American Thoracic Society International Conference, Denver,

CO, May 2011.

12. Lieu T, Albert RK, Krishnan JK, Goss CH, Bush A, Gerald JK, Lee TA. “Pro-Con Debate:

Comparative Effectiveness Research: Fool’s Gold or Promised Land.” Lee TA: Cost-effectiveness

from CER studies should be used to guide treatment decisions: CON. Symposium, 2012 American

Thoracic Society International Conference, San Francisco, CA, May 2012.

13. Lee TA. “Building and Running Decision Models in Microsoft Excel.” ISPOR UIC Student Chapter

Sponsored Event, Chicago, IL, January – March 2016.

B. Invited Lectures, Seminars

1. Evaluating new therapies for rheumatoid arthritis: Fitting Arava® and Enbrel® in the ‘Drug Purchaser

Guidelines’ Northwest Pharmacy Benefits Management Meeting, Seattle, WA, January 1999.

2. Factors influencing adherence with asthma treatments, Respiratory Nursing Conference, Chronic Lung

Disease: Strategies for Promoting Self-Management, Seattle, WA, March 2001.

3. Cost-effectiveness of triamcinolone versus fluticasone in adult asthmatics, College of Pharmacy,

University of Minnesota, Minneapolis, MN, March 2001.

4. Conducting a cost-effectiveness analysis in an equivalence trial, College of Pharmacy, University of

Southern California, Los Angeles, CA, April 2001.

5. Evaluation of cost-effectiveness in an equivalence trial: Azmacort HFA compared to Flovent, Hines VA

Hospital, Hines, IL, May 2001.

Lee TA, Page 20


6. Issues in the evaluation of cost-effectiveness in a pragmatic equivalence trial: the case of Azmacort

versus Flovent, Northwestern University Medical School Seminar Series, Chicago, IL, November 2001.

7. Developing pharmacotherapeutic research in the VA, 2002 VA Health Services Research and

Development National Meeting, Washington, DC, February 2002.

8. The evolution of health economics and cost-effectiveness analysis, Contributed Session: Applying

Evidence-Based Medicine, Outcomes Research and Practice Guidelines in OEM, American College of

Occupational and Environmental Medicine’s 87th American Occupational Health Conference, Chicago,

IL, April 2002.

9. Developing pharmacoeconomic research, 2003 VA Health Services Research and Development National

Meeting, Washington, DC, February 2003.

10. Cost-effectiveness of VRE surveillance strategies in hospitalized patients, UIC College of Pharamcy

Center for Pharmacoeconomics Research Lecture and Seminar Series, Chicago, IL, April 2003.

11. The economic impact of chronic disability, Burden of COPD: Now and Beyond, 2003 AARC Satellite

Symposium, Orlando, FL, July 2003.

12. Economic costs and modeling in COPD, Research Workshop on the Global Burden of COPD,

Vancouver, BC, Canada, October 2004.

13. COPD Modeling, Improving survival in COPD – assessing the value of life-saving therapy, Rome, Italy,

November 2005.

14. Pharmacoepidemiology: Medication Use as Key Health Behavior and Complicated Confounder,

Biomarkers of Social and Health Behavior: Social Influences and Biological Processes, Chicago

Conference on Biomarker Collection in Population-Based Health Research, Chicago, IL, June 2006.

15. Breathe easier: using evidence to improve outcomes for patients with COPD, Regional Symposium,

Milwaukee, WI, November 2006.

16. Costs and cost-effectiveness analysis in pulmonary and critical care medicine, Sunrise Seminar,

American Thoracic Society 2007 International Conference, San Francisco, CA, May 2007.

17. Patients with multiple chronic conditions – healthcare system impact and opportunities for improving

care, Canadian Psychiatric Association, Ottawa, ON, Canada, April 2008.

18. Comparative Effectiveness and the Chicago-area DEcIDE Center, Roundtable Discussion (with Glen

Schumock), Society for Epidemiology Research 41st Annual Meeting, Chicago, IL, June 2008.

19. Epidemiology of multiple chronic conditions and elderly patients with COPD, CONCERT Consensus

Conference, San Diego, CA, May 2009.

20. Comparative effectiveness research in COPD, Meet the Professor Seminar, American Thoracic Society

2010 International Conference, New Orleans, LA, May 2010.

21. Comparative effectiveness research. CCTS 3-Day Summer Program in Clinical and Translational

Research, Chicago, IL, July 2010.

Lee TA, Page 21


22. Safety of long-acting beta-agonists in patients with respiratory disease. 2011 Illinois Society for

Respiratory Care Conference and Exposition, Oak Brook, IL, June 2011.

23. Research at the crossroads of pharmacoepidemiology and pharmacoeconomics: outcomes of

comparative effectiveness research. 6th Annual Midwest Consortium Conference, Chicago, IL, July

2011.



25. Exposures/Interventions. DEcIDE Business Meeting, AHRQ 2011 Annual Conference, Bethesda, MD,

September 2011.

26. Health economics and patient health outcomes research (HEOR). The International Publication Planning

Association 2012 Midwest Meeting, Chicago, IL July 2012.



28. Advancing the quality and relevance of comparative effectiveness research. ISPOR CRC and AMCP

Midwest Affiliate 4th Annual Day of Education, Chicago, IL November 2012.

29. Pragmatic considerations in publication planning when partnering with academic investigators: the case

of outcomes research. The International Publication Planning Association 2013 Annual Meeting, Los

Angeles, CA February 2013.





32. Does improving quality stretch the healthcare dollar? COPD9USA, Chicago, IL June 2015.

33. What is CARMA and what can it do for you? IMEDS Community Call Webinar , June 2016.

34. Staying up-to-date on methods in drug safety: CARMIC insight. Learning from Electronic Data to

Advance Health and Health Care, 2nd Seattle Symposium on Health Care Data and Analytics, Seattle,

WA, October 2016.

35. Illinois PDMP Evaluation Activities, CDC Prevention for States and Data-Driven Prevention Initative

In-Person Meeting, Atlanta, GA, May 2017.

36. Value-based purchasing: theory and practice. Managing the price of pharmaceutical therapies for chronic

lung diseases in the United States, ATS Workshop, Washington, DC, May 2017.

5. RESEARCH PRESENTATIONS

1. Lee TA, Larson LN. “Evaluating the Use and the Quality of Pharmacy Drive-up Services” Poster

Presentation, American Pharmaceutical Association 1998 Annual Meeting, Miami Beach, FL, March

1998.

Lee TA, Page 22


2. Lee TA, Ramsey SD, Neil NJ, Patrick DL, Klastorin TD, Stergachis A, Sullivan SD. “Developing a

Task-based Instrument to Measure Migraine-Related Productivity” Poster Presentation, International

Society for Pharmacoeconomics and Outcomes Research 3rd Annual Meeting, Philadelphia, PA, May

1998. Value Health 1998; 1(1): 82-83.

3. Sullivan SD, Schulz R, Lessler D, Weiss K, Ramsdell J, Lim J, Lee TA, Blough DK, Malone D,

Johnson ES. “Outcomes of Treatment with Inhaled Triamcinolone Acetonide after Twelve Months in

Moderate Adult Asthma: Clinical Results from the ACET-1 Cost-Effectiveness Study” Poster

Discussion Section, American Thoracic Society 1999 International Conference, San Diego, CA, April

1999.

4. Lee TA, Sullivan SD, Blough DK, Weiss K, Lim J, Ramsdell J. “Comparison of Outcome Measures in

a Randomized Trial of Inhaled Triamcinolone Acetonide in Adult Asthmatics” Poster Discussion

Section, American Thoracic Society 1999 International Conference, San Diego, CA, April 1999.

5. Lee TA, Sullivan SD, Ramsey SD, Steger P, Williamson T, Pliel A. “Economic Evaluation of

Systemic Treatments for CMV Retinitis in Persons with AIDS in Switzerland” Poster Presentation,

International Society for Pharmacoeconomics and Outcomes Research 4th Annual Meeting, Crystal

City, VA, May 1999. Value Health. 1999; 2(3): 183.

6. Lee TA, Sullivan SD. “The Effect of Order of Administration of Generic and Disease Specific Health

Status Questionnaires” Talking Poster Presentation, International Society for Pharmacoeconomics and

Outcomes Research 4th Annual Meeting, Crystal City, VA, May 1999. Value Health. 1999; 2(3): 158.

7. Bryant-Comstock L, Mather D, Lee T, Keck P, Li H, Sullivan S. “Treatment of bipolar depression:

clinical and economic outcomes.” Poster Presentation, American Psychiatric Association, 2000 Annual

Meeting, Chicago, IL, May 2000.

8. Murphy MP, Lee TA, Sullivan SD, Yeuh B. “Psychiatric disease in adults diagnosed with chronic

rhinosinusitis.” Podium Presentation, American Academy of Otolaryngology, 2000 Annual Meeting,

Washington, DC, September 2000.

9. Lee TA, McLaughlin T, Sullivan SD, Stanford R. “Asthma costs in managed care patients.” Poster

Presentation, American Academy of Family Physicians, 2001 Scientific Assembly, Atlanta, GA,

October 2001.

10. Lee TA, Sullivan SD, Weiss KB, Georges G. “Comparison of the effectiveness of inhaled

triamcinolone acetonide HFA to inhaled fluticasone propionate CFC in adult asthmatics in a 12-month

pragmatic trial.” Poster Presentation, American Thoracic Society 2002 International Conference,

Atlanta, GA, May 2002.

11. Lee TA, Sullivan SD, Weiss KB, Georges G. “Comparison of the cost-effectiveness of inhaled

triamcinolone acetonide HFA to inhaled fluticasone propionate CFC in adult asthmatics in a 12-month

pragmatic trial.” Poster Presentation, American Thoracic Society 2002 International Conference,

Atlanta, GA, May 2002.

12. Lee TA, Hollingworth W, Sullivan SD. “Directly elicited preferences compared to preferences derived

from the SF-36 in adult asthmatics.” Podium Presentation, International Society for

Pharmacoeconomics and Outcomes Research, 7th Annual International Meeting, Crystal City, VA, May

2002. Value Health. 2002; 5(3): 134-5.

Lee TA, Page 23


13. Lee TA, Stroupe KT, Hacek D, Petersen L. “Evaluation of the cost-effectiveness of three vancomycin-

resistant enterococci surveillance strategies in hospitalized patients.” Poster Presentation, Infectious

Diseases Society of America, 40th Annual Meeting, Chicago, IL, October 2002.

14. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. “Direct medical costs associated with Hepatitis B virus

infection in the United States.” Poster Presentation, International Society for Pharmacoeconomics and

Outcomes Research, 8th Annual International Meeting, Crystal City, VA, May 2003.

15. Lee TA, Raymundo AL, Kim SS, Strauss M, Sullivan SD. “How does an 11-point pain scale relate to

preference estimates in patients with chronic pain and can it be used to predict preferences?” Poster

Presentation, International Society for Pharmacoeconomics and Outcomes Research, 8th Annual

International Meeting, Crystal City, VA, May 2003.

16. Marceille JR, Goins JA, Soni R, Biery JC, Lee TA. “Incidence of congestive heart failure-related

interventions in patients receiving rosiglitazone and insulin.” Poster Presentation, American College of

Clinical Pharmacy, 2003 Annual Meeting, Atlanta, GA, November 2003.

17. Lee TA, Bartle B, Xu J, Davis KJ, Weiss KB. “The association between inhaled corticosteroid use and

fractures in veterans with chronic obstructive pulmonary disease.” Poster Presentation, CHEST 03,

Orlando, FL, October 2003. Chest 2003; 124(4): 166S.

18. Lee TA, Xu J, Weiss KB. “Do follow-up physician visits impact the risk of repeat emergency

department visits in patients with COPD?” Poster Presentation, US COPD Coalition, National COPD

Conference, November 2003.

19. Lee TA, Bartle B, Xu J, Davis KJ, Weiss KB. “The risk of fractures associated with inhaled

corticosteroid use in patients with COPD.” Oral & Poster Presentation, US COPD Coalition, National

COPD Conference, November 2003.

20. Sullivan SD, Lee TA, Blough D, Finkelstein J, Lozano P, Inui T, Carey V, Wagner E, Fuhlbrigge A,

Weiss K. “Cost-effectiveness of Physician Peer Leader Education and Practice-based Redesign in

Managed Care: The Pediatric Asthma Care PORT-II Trial.” Oral Presentation, American Academy of

Allergy, Asthma and Immunology (AAAAI), 60th AAAAI Annual Meeting, March 2004. JACI 2004;

113(2 Suppl): S339.

21. Witt WP, Lee TA, Xu J, Baker DW, Weiss KB. “The mental health impact of living with a spouse with

chronic obstructive pulmonary disease.” Poster Presentation, Society of General Internal Medicine,

2004 Annual Meeting, May 2004.

22. Bednar MM, Wolozin B, Weiss KB, Lee TA. “Increased risk of Alzheimer’s disease diagnosis

following coronary artery bypass graft surgery compared to precutaneous transluminal coronary

angioplasty.” Poster Presentation, 9th Annual International Conference on Alzheimer’s Disease and

Related Disorders, July 2004.

23. Xu J, Lee TA, Witt WP, Durazo-Arvizu R. “Emergency department visits among COPD patients: an

example of repeat recurrent event analysis.” Oral Presentation, American Statistical Association 2004

Joint Statistical Meetings, August 2004.

24. Lee TA, Xu J, Weaver F, Weiss KB. “Risk of pneumonia-related hospitalizations in patients with

chronic lung disease.” Poster Presentation, VA Health Services Research and Development 2005

National Meeting, Baltimore, MD, February 2005.

Lee TA, Page 24


25. Lee TA, Bartle B, Weiss KB. “Characterizing COPD exacerbation patterns in the VA healthcare

system.” Poster Presentation, VA Health Services Research and Development 2005 National Meeting,

Baltimore, MD, February 2005.

26. Smith BM, Stroupe KT, Lee TA, Durazo-Arvizu R, Cao L, Nydam T. “The impact of co-payment

change on discontinuation of VA pharmacy use.” Poster Presentation, VA Health Services Research

and Development 2005 National Meeting, Baltimore, MD, February 2005.

27. Stroupe KT, Smith BM, Lee TA, Durazo-Arvizu R, Cao L, Nydam T. “Medication copay increase and

medication acquisition from the VA.” Poster Presentation, VA Health Services Research and

Development 2005 National Meeting, Baltimore, MD, February 2005.

28. Lee TA, Bartle B, Weiss KB. “Characterizing COPD exacerbation patterns in the VA healthcare

system.” Poster Presentation, 2005 American Thoracic Society International Conference, San Diego,

CA, May 2005.

29. Lee TA, Bartle B, Weiss KB. “Patterns of Respiratory Medication Use in a VA COPD Cohort, 1999-

2002.” Poster Presentation, 2005 American Thoracic Society International Conference, San Diego, CA,

May 2005.

30. Lee TA, Xu J, Weaver F, Weiss KB. “Risk of Pneumonia-Related Hospitalizations in Patients with

Chronic Lung Disease.” Poster Presentation, 2005 American Thoracic Society International


31. Lee TA, Bartle B, Weiss KB. “Health System Variation in COPD Exacerbation Rates.” Poster

Presentation, 2005 American Thoracic Society International Conference, San Diego, CA, May 2005.

32. Lee TA, Bartle B, Weiss KB. “Spirometry Use in Clinical Practice in Patients with COPD.” Poster


33. Lee TA, Fuhlbrigge AL, Finkelstein JA, Sullivan SD, Lozano P, Carey V, Inui TS, Weiss KB.

“Agreement between Caregiver Reported Healthcare Utilization and Administrative Data for Children

with Asthma” Poster Presentation, 2005 American Thoracic Society International Conference, San

Diego, CA, May 2005.

34. Lee TA, Bartle B, McLaughlin T, Dirani R. “Adherence to respiratory medications in VA patients with

chronic lung disease.” Poster Presentation, International Society for Pharmacoeconomics and

Outcomes Research, 10th Annual International Meeting, Washington, DC, May 2005.

35. Grim S, Cannon J, Lee TA, Crank C, Patel G, Proia L, Labuszewski L, Mullane K, Jancel T, Clark N.

“Utilization of newer antifungals in a large metropolitan setting.” Poster Presesntation, Focus on

Fungal Infections 16, Las Vegas, NV, March 2006.

36. Scheetz MH, Lee TA, Noskin GA, Postelnick MJ, Bolon MK. “A cost-effectiveness analysis of an

antimicrobial utilization team on blood stream infections.” Poster Presentation, Society for Healthcare

Epidemiology of America (SHEA) 16th Annual Meeting, Chicago, IL, March 2006.

37. Venkatesh A, Lee TA, Barnard C, Noskin GA. “Adverse events among hospitalized patients

significantly increase costs.” Poster Presentation, Society for Healthcare Epidemiology of America 16th

Annual Meeting, Chicago, IL, March 2006.

Lee TA, Page 25


38. Lee TA, Sullivan SD, Buist AS, Vollmer W, Weiss KB. “Estimating the future economic burden of

COPD.” Poster Presentation, 2006 American Thoracic Society International Conference, San Diego,

CA, May 2006.

39. Jordan N, Lee TA, Valenstein M, Weiss KB. “Factors associated with evidence-based depression

treatment for persons with COPD and depression.” Poster Presentation, 2006 American Thoracic

Society International Conference, San Diego, CA, May 2006.

40. Lee TA, Pickard AS, Bartle B, Weiss KB. “Prescription for longer life: a diagnosis of osteoarthritis?”

Poster Presentation, International Society for Pharmacoeconomics and Outcomes Research, 11th

Annual International Meeting, Philadelphia, PA, May 2006.

41. Weiss KB, Lee TA, Sullivan SD, Vollmer W, Buist AS. “Health status comparison of patients with

COPD throughout the world: the BOLD Initiative.” Poster Presentation, 2006 European Respiratory

Society Congress, Munich, Germany, September 2006.

42. Grim S, Gupta S, Holloway M, Lee TA, Paek J, Janda W, Clark N. “Candida Bloodstream Infections

(CBSI) at a University Hospital 2001-2004.” Poster Presentation, Infectious Diseases Society of

America, 44th Annual Meeting, Toronto, ON, October 2006.

43. Lee TA, Sin DD, Sullivan SD. “Cost-effectiveness of inhaled corticosteroids in COPD: results from

the BOLD economic model using ISEEC results.” Poster Presentation, CHEST 2006, Salt Lake City,

UT, October 2006. Chest 130(4): 179S.

44. Lee TA, Gao CY, Walter B, O’Connor GT, Sullivan SD, Buist AS, Weiss KB. “Rate of disease

progression in patients with COPD in the Framingham Heart Study cohort.” Slide Presentation,

CHEST 2006, Salt Lake City, UT, October 2006. Chest 130(4): 97S.

45. Ogale SS, Lee TA, Sullivan SD. “The risk of cardiovascular events associated with inhaled long-acting

beta-2-adrenoreceptor agonists in patients with chronic obstructive pulmonary disease.” Slide

Presentation, CHEST 2006, Salt Lake City, UT, October 2006. Chest 130(4): 121-S-122S.

46. Murthy K, Grobman WA, Lee TA, Holl JL. “Medical malpractice pressures for obstetrician-

gynecologists are associated with late preterm induction in Illinois.” Poster Presentation, 2007 Pediatric

Academic Societies’ Annual Meeting, Toronto, Canada, May 2007.

47. Murthy K, Grobman WA, Lee TA, Holl JL. “The effect of medical malpractice pressures for

obstetricians on term induction rates in Illinois.” Poster Presentation, 2007 Pediatric Academic

Societies’ Annual Meeting, Toronto, Canada, May 2007.

48. Murthy K, Grobman WA, Lee TA, Holl JL. “Racial disparities in term and post-term induction rates in

Illinois.” Podium Presentation, 2007 Pediatric Academic Societies’ Annual Meeting, Toronto, Canada,

May 2007.

49. Lee TA, Pickard AS, Bartle B, Schumock GT, Weiss KB. “Increased risk of mortality associated with

use of ipratropium and theophylline in COPD patients.” Poster Presentation, 2007 American Thoracic

Society International Conference, San Francisco, CA, May 2007.

50. Lee TA, Pickard AS, Bartle B, Schumock GT, Weiss KB. “Outcomes associated with theophylline use

in COPD patients.” Poster Presentation, 2007 American Thoracic Society International Conference,

San Francisco, CA, May 2007.

Lee TA, Page 26


51. Lee TA, Gislason T, Sullivan SD, Benediktsdottir B, Gudmundsson G, Buist AS, Weiss KB. “Future

economic burden of COPD in Iceland: results from the BOLD initiative.” Poster Presentation, 2007

American Thoracic Society International Conference, San Francisco, CA, May 2007.

52. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. “Cardiovascular outcomes associated with

anticholinergic medications.” Poster Presentation, 2007 American Thoracic Society International

Conference, San Francisco, CA, May 2007.

53. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. “Long-acting beta2-agonists and all-cause

mortality in COPD.” Poster Presentation, 2007 American Thoracic Society International Conference,

San Francisco, CA, May 2007.

54. Valenstein M, Kavanagh J, Ganoczy D, Lee T, Smelson D, Jensen A. “The Impact of a Pharmacy-

Based Intervention on Antipsychotic Adherence Among Patients with Serious Mental Illness.”

AcademyHealth Annual Research Meeting, Orlando, FL, June 2007.

55. Cannon JP, Clark NM, Lee T, Setlak P, Grim SA. The incidence of carbapenem (CBP)-related

seizures: a meta-analysis. American College of Clinical Pharmacy Annual Meeting, Denver, CO,

October 2007.

56. Lee TA, Pickard AS, Bartle B, Weiss KB. “Medication Safety in COPD Patients: The Risk of

Respiratory and Cardiovascular Deaths Associated with Treatment in Veterans with COPD.” Oral

Presentation, VA Health Service Research and Development 2008 National Meeting, Baltimore, MD,

February 2008.

57. Lee TA, Ogale SS, Sullivan SD, Au D. “Risk of All-Cause Mortality Associated with Long-Acting

Beta-Agonist use in Veterans with COPD.” Oral Presentation, VA Health Service Research and

Development 2008 National Meeting, Baltimore, MD, February 2008.

58. Lee TA, Tan W, Fitzgerald M, Sin D, Marra C, Weiss KB, Sullivan SD. “Future Economic Burden of

COPD in Canada: Results from the BOLD Initiative.” Poster Presentation, 2008 American Thoracic

Society International Conference, Toronto, ON, May 2008.

59. Lee TA, Pickard AS, Bartle B, Weiss KB. “COPD Medication Safety: Risk of Respiratory and

Cardiovascular Deaths Associated with Treatment.” Poster Presentation, 2008 American Thoracic

Society International Conference, Toronto, ON, May 2008.

60. Lee TA, Wilke CT, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS. “Comparative

effectiveness of ipratropium in COPD patients.” Poster Presentation, International Society for

Pharmacoeconomics and Outcomes Research, 14th Annual International Meeting, Orlando, FL, May

2009.

61. Chang Y, Lee TA. “The economic burden of chronic obstructive pulmonary disease due to smoking.”


Annual International Meeting, Orlando, FL, May 2009.

62. Bautista A, Stein BD, Lee TA, Meltzer DO, DiDomenico R, Krishnan JA, Schumock GT. “Specificity

of administrative data for identifying heart failure patients for hospital quality performance initiatives.”


Annual International Meeting, Orlando, FL, May 2009.

Lee TA, Page 27


63. Lee TA, Wilke CT, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS. “Outcomes

associated with tiotropium use in COPD patients.” Podium Presentation, International Society for

Pharmacoeconomics and Outcomes Research, 14th Annual International Meeting, Orlando, FL, May

2009.

64. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. “Determinants of Spirometry Use and Accuracy of COPD in

Primary Care.” Poster Presentation, 2010 American Thoracic Society International Conference, New

Orleans, LA, May 2010.

65. Ly V, Brehm R, Cohen M, Kaplow D, Lee TA, Cutaia M. “Development of a Long-Term Oxygen

Therapy Registry to Study Practice Variability Within a Regional VA Health Care System (VISN3).”

Poster Presentation, 2010 American Thoracic Society International Conference, New Orleans, LA,

May 2010.

66. Lee TA, Joo MJ, Krishnan JA, Wilke CT, Schumock GT, Pickard AS. “Risk of Stroke Associated with

Ipratropium and Tiotropium Use in Patients with COPD.” Podium Presentation, 2010 American

Thoracic Society International Conference, New Orleans, LA, May 2010.

67. Brehm R. Ly V, Cohen M, Kaplow D, Lee TA, Cutaia M. “Survival Analysis of Patients on Long-

Term Oxygen Therapy Using an Electronic Record Registry Within a Regional VA Health Care

System.” Poster Presentation, 2010 American Thoracic Society International Conference, New Orleans,

LA, May 2010.

68. Stein BD, Bautista A, Charbeneau JT, Schumock GT, Lee TA, Lauderdale DS, Krishnan JA. “Validity

of ICD-9 code algorithms for identifying patients hospitalized for acute exacerbation of COPD.”

Podium Presentation, 2010 American Thoracic Society International Conference, New Orleans, LA,

May 2010.

69. Wilke CT, Lin FJ, Lee TA, Lambert BL, Joo MJ, Pickard AS. “Variability in measurement of

medication exposure in pharamcoepidemiologic studies of COPD.” Podium Presentation, 26th

International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK,

August 2010.

70. Wilke CT, Lee TA, Lambert BL, Joo MJ, Pickard AS. “Sensitivity of Hazard Estimates to Exposure

Definition: A Simuluation Study.” Plenary Podium Presentation, 26th International Conference on

Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK, August 2010.

71. Joo MJ, Au DH, Fitzgibbon M, Lee TA. “Accuracy of physician diagnosis of COPD and determinants

of spirometry use.” Poster Presentation, 2011 American Thoracic Society International Conference,

Denver, CO, May 2011.

72. Lewis S, Au DH, Carson SS, Lee TA, Lindenauer PK, McBurnie MA, Mularski RA, Vollmer WM,

Krishnan JA. “Novel multi-institutional data infrastructure for comparative effectiveness research in

COPD (COPD DataHub).” Poster Presentation, 2011 American Thoracic Society International

Conference, Denver, CO, May 2011.

73. McKell JL, Allen NB, Daviglus ML, Joo MJ, Lee TA. “Variations in definitions of COPD across

ethnic groups using the NHANES database.” Poster Presentation, 2011 American Thoracic Society

International Conference, Denver, CO, May 2011.

Lee TA, Page 28


74. Bunyan A, Lee TA, Au DH, Joo M. “Patient characteristics associated with misdiagnosis of COPD in

primary care.” Poster Presentation, 2012 American Thoracic Society International Conference, San

Francisco, CA, May 2012.

75. McKell JL, Conrad KJ, Joo M, Lee TA. “Reliability of a survey to determine primary care physicians

perspectives on the use of spirometry for the diagnosis of COPD.” Poster Presentation, 2012 American


76. Lin FJ, Lee TA, Wong PS, Pickard AS. “Evaluation of changes in guidelines for medication

management of stable chronic obstructive pulmonary disease.” Poster Presentation, 2012 American


77. Adimadhyam S, Schumock GT, Walton SM, Joo MJ, McKell JL, Lee TA. “Increased risk of

arrhythmias associated with inhaled anticholinergics in children, adolescents and young adults with

asthma.” Poster Presentation, 2012 American Thoracic Society International Conference, San

Francisco, CA, May 2012.

78. Sumino K, O’Brian KK, Bartle B, Au DH, Castro M, Lee TA. “Effects of co-existing chronic

conditions on mortality and morbidity in adult asthma.” Poster Presentation, 2012 American Thoracic

Society International Conference, San Francisco, CA, May 2012.

79. Joo M, Sharp L, Lee TA, Au DH, Fitzgibbon M. “Underutilization of spirometry in COPD: a

qualitative study of primary care physicians.” Poster Presentation, 2012 American Thoracic Society

International Conference, San Francisco, CA, May 2012.

80. Prieto-Centurion V, Rolle AG, Au DH, Carson SS, Henderson A, Lee TA, Lindenauer PK, McBurnie

M, Mularski RA, Naureckas ET, Vollmer W, Krishnan JA. “A comparison of three methods used to

identify patients with COPD.” Poster Presentation, 2013 American Thoracic Society International

Conference, Philadelphia, PA, May 2013.

81. Pickard AS, Lee TA, Lin FJ, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski RA,

Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA. “Assessment of health-related quality of

life using EQ-5D-5L in patients with chronic obstructive pulmonary disease (COPD): experience in the

CONCERT cohort.” Poster Presentation, 2013 American Thoracic Society International Conference,

Philadelphia, PA, May 2013.

82. Pickard AS, Lin FJ, Lee TA, Sharma G, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski

RA, Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA. “Evaluation of the functional

assessment of the chronic illness therapy (FACIT)-dyspnea short form in chronic obstructive

pulmonary disease.” Poster Presentation, 2013 American Thoracic Society International Conference,


83. Bunyan A, Lee TA, Au DH, Joo MJ. “Healthcare utilization associated with misdiagnosis of COPD in

primary care.” Poster Presentation, 2013 American Thoracic Society International Conference,


84. Pickard AS, Lee TA, Lin FJ, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski RA,

Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA. “Measuring health using the patient

reported outcomes measurement information system (PROMIS-43) in chronic obstructive pulmonary

disease (COPD): experience in the CONCERT cohort.” Poster Presentation, 2013 American Thoracic

Society International Conference, Philadelphia, PA, May 2013.

Lee TA, Page 29


85. Feemster LC, Ma J, McBurnie MA, Carson SS, Henderson AG, Lee TA, Lindenauer PK, Mularski

RA, Naureckas ET, Vollmer WM, Krishnan JK, Au DH. “The association of body mass index and

waist circumference with six-minute walk distance and symptoms among patients with COPD.” Poster

Presentation, 2013 American Thoracic Society International Conference, Philadelphia, PA, May 2013.

86. Joo MJ, Lee TA, Au DH, Fitzgibbon M. “Underutilization of spirometry in COPD: a survey of primary

care physicians.” Poster Presentation, 2013 American Thoracic Society International Conference,


87. Dilokthornsakul P, Chiakunapruk N, Lee TA. “Time-specific propensity score analysis for

observational study: a case study estimating the effectiveness of thiazolidinedione use.” Podium


International Meeting, New Orleans, LA, May 2013.

88. Dilokthornsakul P, Schumock GT, Chiakunapruk N, Lee TA. “Estimating time-specific propensity

scores: a case study of the effectiveness of inhaled long-acting beta-agonists on asthma exacerbations.”

Poster Presentation, International Society for Pharmacoepidemiology, 29th International Conference on

Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada, August 2013.

89. Dilokthornsakul P, Chiakunapruk N, Nimpitakpong P, Jeanpeerapong N, Jampachaisri K, Lee TA.

“Factors predicting medication oversupply in Thailand: a mixed model regression analysis.” Poster


International Meeting, Montreal, Canada, May 2014.

90. Zueger PM, Lee TA. “Health care costs associated with acute cardiovascular events in a COPD patient

population.” Poster Presentation, International Society for Pharmacoeconomics and Outcomes

Research, 19th Annual International Meeting, Montreal, Canada, May 2014.

91. Dilokthornsakul P, Lee TA. “The association between tiotropium use and cardiac arrhythmia

hospitalization in patients with chronic obstructive pulmonary disease using a self-controlled case

series design.” Poster Presentation, International Society for Pharmacoeconomics and Outcomes

Research, 19th Annual International Meeting, Montreal, Canada, May 2014.

92. Ursan ID, Lee WJ, Lee TA. “Insulin or thiazolidinedione use and fracture risk in patients with chronic

obstructive pulmonary disease and diabetes mellitus.” Poster Presentation, International Society for

Pharmacoeconomics and Outcomes Research, 19th Annual International Meeting, Montreal, Canada,

May 2014.

93. Lee WJ, Lee TA. “Risk of acute angle-closure glaucoma associated with inhaled anticholinergic agents

in a COPD population.” Poster Presentation, International Society for Pharmacoeconomics and

Outcomes Research, 19th Annual International Meeting, Montreal, Canada, May 2014.

94. Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M,

Merrigan JFP, Duh MS. “Assessment of COPD exacerbation risk: utilizing health claims data to

develop and validate a risk equation.” Poster Presentation, 2014 American Thoracic Society

International Conference, San Diego, CA, May 2014.

95. Joo MJ, Au DH, Fitzgibbon M, Bunyan A, Vinicky M, Lee TA. “Comparative effectiveness of a

COPD assessment and management bundle versus usual care: baseline characteristics.” Poster


Lee TA, Page 30


96. Sumino K, Castro M, O’Brian K, Bartle B, Au DH, Lee TA. “Impact of consolidation of combination

therapy in obstructive lung disease.” Poster Presentation, 2014 American Thoracic Society


97. Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M,

Merrigan JFP, Duh MS. “Risk assessment of first severe COPD exacerbation using predictive models

based on health claims data.” Poster Presentation, 2014 American Thoracic Society International


98. Haas KP, Lee TA, Dilokthornsakul P, Joo MJ. “Survey to determine perspectives on the use of

spirometry in COPD: users versus non-users.” Poster Presentation, 2014 American Thoracic Society


99. Dilokthornsakul P, Lee TA. “The association between pneumococcal vaccine and thrombocytopenia in

elderly patients with chronic obstructive pulmonary disease: a case-crossover study.” Poster

Presentation, 30th International Conference on Pharmacoepidemiology and Therapeutic Risk

Management, Taipei, Taiwan, October 2014.

100. Lee WJ, Lee TA, Pickard AS, Shoaibi A, Schumock GT. “Feasibility of alternative methods for health

outcomes of interest algorithm validation.” Poster Presentation, 30th International Conference on

Pharmacoepidemiology and Therapeutic Risk Management, Taipei, Taiwan, October 2014.

101. Patel VA, Walton SM, Galanter WL, Lee TA, Schumock G, Nutescu EA. The validity of algorithms

for identifying suspected and confirmed heparin-induced thrombocytopenia. Poster Presentation,

International Society for Pharmacoeconomics and Outcomes Research, 20th Annual International

Meeting, Philadelphia, PA, May 2015.

102. Patel VA, Galanter WL, Lee TA, Schumock G, Nutescu EA, Hohmann SF, Walton SM. Comparative

effectiveness and safety of argatroban and bivalirudin in patients with suspected heparin-induced

thrombocytopenia. Poster Presentation, International Society for Pharmacoeconomics and Outcomes

Research, 20th Annual International Meeting, Philadelphia, PA, May 2015.

103. Xing S, Lee TA. Second Generation Antipsychotics and Diabetes Risk Among Children and Young

Adults 6-24 Years of Age. Podium Presentation, International Society for Pharmacoepidemiology,

Mid-Year Meeting, Baltimore, MD, April 2016.

104. Manzoor BS, Lee TA, Sharp L, Galanter WL, Walton SM, Nutescu EA. A higher percentage of newly

initiated direct oral anticoagulant users switch back to traditional therapy. Podium Presentation,

International Society for Pharmacoeconomics and Outcomes Research, 22nd Annual International

Meeting, Boston, MA, May 2017.

105. Manzoor BS, Walton SM, Lee TA, Sharp LK, Galanter WL, Nutescu EA. Real-world adherence and

persistence with direct oral anticoagulants in adults with atrial fibrillation. Poster Presentation, The

International Society on Thrombosis and Hemostatis Congress, Berlin, Germany, July 2017.

6. Research Support5,**

Active

Martin (PI) 12/17 – 11/18 $168,327

Gilead Sciences

5 Unless noted, funding amounts represent total costs ** Indicates total direct costs

Lee TA, Page 31


IN-US-342-4530

Expanding Hepatitis C virus care and cure: national experience using a clinical pharmacist-driven model

Role: Co-Investigator

Touchette (PI) 11/17 – 6/18 $125,000

Institute for Clinical and Economic Review

Economic evaluation of erenumab in the prophylactic treatment of migraine


Investigators: Touchette D, Lee TA, Walton S

Touchette (PI) 3/17 – 3/18 $125,000

Institute for Clinical and Economic Review

Institute for Clinical and Economic Review Consulting Contract


Investigators: Touchette D, Lee TA, Pickard AS, Schumock GT, Walton S

Joo (PI) 9/16 – 7/19 $1,500,000

Agency for Healthcare Research and Quality

1R01HS024964-01

Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)


Lee (PI) 9/15 – 9/19 $420,000

Centers for Disease Control

1U17CE002739-01

Evaluation plan for prescription drug overdose prevention for states: Illinois

Role: Principal Investigator

Daviglus (PI) 4/15 – 3/20

NHLBI

5T32HL125294-02

Training in CVD Epidemiology and Related Chronic Diseases in Minority Populations

Role: Mentor

Completed

Gerald (PI) 8/13 – 4/17 $3,155,975

NHLBI

1R18HL110858-01A1

The cost effectiveness of school-based supervised asthma therapy


Investigators: Gerald LB, Gerald J, Lee TA

Lee (PI) 12/15 – 12/16 $60,000

IMEDS-Reagan Udall Foundation

UIC CPR Center for Annotating Research Methods and Analyses (CARMA): Focused on New Approaches

in Utilizing ‘Real World’ Data


Boudreau (PI) 1/14 – 6/15 $46,572**

FDA

HHSF223200910006I

NDI plus linkage to the mini-sentinel distributed data network

Lee TA, Page 32



Lee (PI) 7/13 – 6/15 $184,953**

Astellas

Astellas-UIC fellowship in pharmacoepidemiology and pharmacovigilance

Role: PI

Schneeweiss (PI) 1/14 – 3/15 $18,112**

FDA

HHSF223200910006I

Analytic methods to assess the robustness of drug safety monitoring results


Pickard (PI) 8/13 – 8/14 $35,454

ARIAD Pharmaceuticals, Inc

BCR-ABL1 mutations conferring treatment resistance


Investigators: Pickard AS, Lee TA

Schumock (PI) 10/12 – 8/13 $205,200

FDA

HHSF22301008T-0009

Alternative methods for health outcomes of interest validation


Investigators: Schumock GT, Lee TA, Pickard AS

Pizer (PI)

VA HSR&D 4/11 – 9/13 $658,603**

IIR 10-136

Comparative effectiveness of anti-diabetic medication alternatives for Veterans


Investigators: Pizer S, Edelman D, Conlin P, Lee TA, Gellad W

Jordan (PI)

VA HSR&D 10/10 – 6/13 $216,800**

Depression care facility-level variation for persons with multimorbidity


Investigators: Jordan N, Lee T, Sohn M, Valenstein M, Yano E

Evans (PI)

VA HSR&D 4/11 – 3/13 $219,399**

C. difficile outcomes and effectiveness of treatment strategies in SCI


Investigators: Evans C, Smith B, Lee TA

Lee (co-PI)

NHLBI 9/09 – 8/12 $7,439,784

1RC2HL101618-01

CONCERT-Clinical Effectiveness Research (CONCERT-CER)

Role: Co-PI

Investigators: Krishnan J (co-PI), Au D (co-PI), Carson S (co-PI), Lee T (co-PI), Lindenauer P (co-PI),

McBurnie M (co-PI), Mularski R (co-PI), Henderson A, Naurekas E, Pickard A, Schumock G, Vollmer W

Lee TA, Page 33


Hynes (PI)

VA HSR&D 5/09 – 4/12 $846,200**

IIR 08-354

Clinical guidelines for ESA use in cancer: impacts on clinical practice


Investigators: Hynes D, Lee T, Stroupe K, Tarlov E

Hynes (PI)

VA HSR&D 8/03 – 5/11 $1,221,717**

IIR 03-196

Quality and costs of colon cancer care in VA and Medicare


Investigators: Hynes D, Bennett C, Durazo-Arvizu R, Lee T, Sohn M, Tarlov E

Jordan (PI)

AHRQ 9/08 – 8/11 $249,796

R21HS017635-1

Effect of chronic illness complexity on evidence-based depression treatment


Investigators: Jordan N, Lee T, Sohn M

Weiss (PI)

RWJ 12/07 – 12/10 $1,178,905

Characterizing costs and episodes of care


Investigators: Weiss K, Lee T, Manheim L, Stroupe K

Hidalgo (PI)

DOD 10/08 – 9/10 $204,993

HHSP23320045013XI

Complex chronic care among Tricare beneficiaries: cost effective treatment strategies

Role: Project Lead Investigator

Investigators: Hidalgo J, Jordan N, Lee T, Sohn M, Stroupe K

Lee (PI)

VA HSR&D 7/06 – 12/10 $349,537**

IIR 05-293

NSAID Related Adverse Events: Evaluating Risk Using Clinical Information


Investigators: Lee T, Mak E, Sohn M, Weiss K

Pickard (PI)

AHRQ 11/08 – 12/09 $275,948

HHSA290-2005-0038-I-TO4-WA2

Development of a multicenter prospective study to assess the effectiveness of treatment for COPD


Investigators: Pickard A, Joo M, Krishnan J, Lee T, Schumock G

Pickard (PI)

AHRQ 8/07 – 12/08 $224,051

HHSA290-2005-0038-I-TO4-WA1

Lee TA, Page 34


Comparative effectiveness of anticholinergic medications in patients with chronic obstructive pulmonary

disease (COPD)


Investigators: Pickard A, Joo M, Krishnan J, Lee T, Schumock G, Stroupe K

Lee (PI)

VA HSR&D 10/04 – 9/07 $651,900**

IIR 03-307

Outcomes associated with salmeterol use in obstructive lung disease


Investigators: Lee T, Weiss K

Pickard (PI)

EuroQol Group 1/07 – 12/07 $9,200

Quality of life according to the EQ-5D in asthma and COPD


Investigators: Pickard A, Lee T

Lee (PI)

GlaxoSmithKline 12/06 – 11/07 $136,165

Assessment of the use and outcomes of antithrombotics following orthopedic surgery in the VA


Investigators: Lee T, Pickard A

Schumock (PI)

AHRQ 10/05 – 9/06 $249,851

HHSA29020050038I

Outcomes of COPD Management


Investigators: Schumock G, Lee T, Weiss K

Armstrong (PI)

VA HSR&D 1/03 – 12/06 $812,700**

IIR 20-059-2

Dermal Thermometry and Self-Care in High Risk Diabetic Patients


Investigators: Armstrong D, Lavery L, Lee T, Wendel C

Valenstein (PI)

VA HSR&D 3/04 – 10/06 $153,019**

IIR 01-074

Improving antipsychotic adherence among patients with serious mental illness

Role: Co-Investigator / Site PI

Investigators: Valenstein M, Blow F, Dalack GW, Grabowski J, Lee T, Poddig B, Reilly P, Ronis D,

Smelson D

Sheilds (PI)

DoD 9/04 – 3/06 $330,873

Consortium on complex chronic illness: improving health care experiences and quality of care among

military health system beneficiaries living with chronic illness


Investigators: Sheilds A, Vogeli C, Gibson T, Lee T, Weiss K, Hidalgo J, Marder W, Blumenthal D

Lee TA, Page 35


Walton (PI)

Takeda 10/03 – 9/05 $107,000

Assessment of the risk of large and small vessel disease in patients with type 2 diabetes


Investigators: Walton S, Lee T, Pickard A

Lee (PI)

Pfizer 9/04 – 8/05 $106,305

Population-based COPD progression estimates


Investigators: Lee T, Sullivan S, Weiss K

Lee (PI)

NDC Health 9/04 – 8/05 $125,551

Medication adherence in patients with respiratory disease


Investigators: Lee T, McLaughlin T

Stroupe (PI)

VA HSR&D 7/03 – 6/05 $402,960**

ECI 02-220

Effect of increased co-payment on pharmacy use in the VA


Investigators: Stroupe K, Smith B, Cunningham F, Hynes D, Lee T, Weiss K

Lee (PI)

AAMC-CDC 10/02 – 9/04 $171,346

MM-0204-03/03

Pneumococcal Pneumonia in VA Patients with Lung Disease


Investigators: Lee T, Weaver F, Weiss K

Weiss (PI)

AHRQ 9/02 – 9/04 $497,611

Outcomes assessment in pediatric asthma


Investigators: Weiss K, Lozano P, Fuhlbrigge A, Finkelstein J, Inui T, Sullivan SD, Lee T

Lee (PI)

AstraZeneca 7/03 – 6/04 $63,199

Examining variations in care and exacerbations in patients with COPD



Lee (PI)

Alliance (Boehringer-Ingelheim – Pfizer) 3/03 – 8/04 $91,704

Characterizing the Burden of Chronic Obstructive Pulmonary Disease


Investigators: Lee T, Weiss K, Van De Graaff W

Weiss (PI)

Lee TA, Page 36


MCR Vision 6/02 – 9/04 $169,175

Model of the current and future healthcare expenditures for chronic obstructive pulmonary disease


Investigators: Weiss K, Lee T, Sullivan S

Lee (PI)

VA HSR&D 9/03 – 12/03 $9,360

LIP 42.078

Comparison of multiple proxy and patient perspectives on quality of life


Investigators: Lee T, Pickard A

Lee (PI)

Pfizer 7/03 – 6/04 $20,808

Assessment of the association between the development of Alzheimer’s disease and exposure to general

anesthesia


Investigators: Lee T, Weiss K, Wolozin B

Lee (PI)


Inhaled corticosteroid use and the risk of fractures in COPD patients in the VA



Lee (PI)

VA HSR&D 6/02 – 9/02 $8,000**

LIP 42.066

Development of an algorithm to identify community acquired pneumococcal pneumonia using pharmacy

and outpatient data


Investigators: Lee T, Weiss K, Weaver F

Lee (PI)


Synopsis of the Functional Independence Measure


Investigators: Lee T

Lee (PI)


Evaluation of selected preference, health status, and function assessment instruments


Investigators: Lee T

Lee (PI)

American Pharmaceutical Association 1/97 – 5/97 $1,000

Innovative Research Grant

Evaluating the Quality of Pharmacy Drive-Up Services


Investigators: Lee T, Larson L

Lee TA, Page 37


7. SERVICE

A. Memberships in Professional and Scientific Organizations and Societies

1995 – 2009 American Pharmaceutical Association

1997 – 2002 International Health Economics Association

1997 – present International Society for Pharmacoeconomics and Outcomes Research

1997 – 2002 American Association of Colleges of Pharmacy

1999 – 2003 Drug Information Association

1999 – 2003 Society for Medical Decision Making

2009 – present American Thoracic Society

2009 – 2014 Academy of Managed Care Pharmacy

B. Journals***

Reviewer Inquiry, Pharmacoeconomics, Quality of Life Research***, Journal of Clinical Outcomes

Management, Value in Health, Medical Care, Expert Opinion on Pharmacotherapy,

European Respiratory Journal, Medical Decision Making, Journal of COPD, Archives

of Internal Medicine, JAMA, Chest, Journal of General Internal Medicine,

Pharmacotherapy***, Thorax, Annals of Internal Medicine***, Journal of Aging***,

Annals ATS***, Canadian Medical Association Journal***, PLOS One***, BMC Health

Services Research***, Annals of Pharmacotherapy***

C. Committee Service

University / Institution Committee Service

1996 – 1997 Drake University, Academic Integrity Committee, Member

1997 University of Washington, Graduate Admissions Committee, Member

2007 – 2008 Institute for Healthcare Studies, Post-doctoral Fellowship Executive Committee, Member

2008 – 2011 Research and Development Committee, Hines VA Hospital, Member

2009 – present Corporate Research Data Warehouse Clinical Advisory Committee, Bioinformatics Core,

UIC Center for Clinical and Translational Sciences (CCTS) , Member

2009 – 2011 Center for Pharmacoecomonic Research Executive Committee, University of Illinois at

Chicago, Member

2010 Promotion guidance committee, Center for Management of Complex Chronic Care

(CMC3), Hines VA Hospital, Member

2010 Research Strategic Plan Development Committee, Hines VA Hospital, Member

2010 Grant Submission Process Improvement Committee, Center for Management of Complex

Chronic Care (CMC3), Hines VA Hospital, Member

2010 Faculty search committee, Rockford Pharmacy Administration Faculty Position, University

of Illinois at Chicago, Member

2010 – 2011 UIC Center for Clinical and Translational Sciences (CCTS) Comparative Effectiveness

Research Symposium / Workshop Planning Committee, Member

2010 – 2012 Chicago-area Clinical and Translational Sciences Awards Comparative Effectiveness

Research Strategic Planning Committee, University of Illinois at Chicago representative

(1 of 2 UIC members), Member

2013 – present Lon Larson Engaged Practitioner Award, Drake University, Selection Committee Member

2013 – present Educational Policy Committee, College of Pharmacy, University of Illinois at Chicago,

Committee Member

2017 – present Chancellor’s Intercollegiate Advisory Committee, University of Illinois at Chicago,

Committee Member

2017 Faculty search committee, Biopharmaceutical Sciences Department Head, University of

Illinois at Chicago, Member

*** Indicates reviewed for journal in last two years

Lee TA, Page 38


2017 PSOP Promotion and Tenure Committee, College of Pharmacy, University of Illinois at

Chicago, Chair

Regional, National or International Committees

2002 VA HSR&D 2002 Annual Meeting Poster Awards Committee, Member

2002 AHRQ Evidence-based Medicine Report on Seasonal Allergies, Effect on Working

Populations, Peer reviewer

2002 JCAHO Disease-Specific Care Asthma Expert Panel, Panel Member

2002 – 2003 Integrating Economic Analysis into Cancer Clinical Trials Conference, Chicago, IL Co-

Chair

2003 Contributed Research Review Committee, ISPOR 8th Annual International Meeting

2003 – 2004 Medication Compliance Bibliography Working Group, ISPOR Medication Compliance

Special Interest Group

2003 – 2010 Salt Lake Informatics and Patient Safety Enhancement Program, Steering Committee

Member

2003 – 2011 VIReC Pharmacy Data Workgroup, Member

2006 – 2010 ATS Project Committee: How does lack of health insurance contribute to health disparities

for patients with lung disease and critical illness?, Member

2006 – 2007 ISPOR, 2007 Annual Meeting, Contributed Research Review Committee, Co-Chair

2007 ISPOR Chicago-region Chapter, Organizing Committee

2007 ISPOR Chicago-region Chapter, Director

2007 – 2011 Chicago-area DEcIDE, Steering Committee Member

2008 – 2013 Academy of Managed Care Pharmacy (AMCP) Format for Formulary Submissions

Executive Committee, Member

2008 – 2014 ISPOR, Bernie J. O’Brien New Investigator Award Committee, Member

2010 – 2012 Respiratory Measurement Advisory Panel, National Center for Quality Assurance, Member

2014 – present Respiratory Measurement Advisory Panel, National Center for Quality Assurance, Member

2015 – present Agency for Healthcare Research and Quality Healthcare (AHRQ) Horizon Scanning

System (HHSS), Expert Commenter

2016 – present VA Information Resource Center (VIReC) Pharmacy Information Technical Advisory

Group, Member

Scientific Merit Review Panels

2005 VA HSR&D Scientific Merit Review Board (SMRB), Chronic Disease Management and

Behavioral Processes Review Group, Ad hoc reviewer

2005 VA HSR&D Scientific Merit Review Board (SMRB), Quality Measurement and

Effectiveness Review Group, Ad hoc reviewer

2005 Michael Smith Foundation for Health Research, Career Awards, External reviewer

2005 – 2009 VA HSR&D Scientific Merit Review Board (SMRB), Chronic Diseases and Quality

Measurement & Effectiveness, Member

2007 AHRQ, Centers for Education and Research in Therapeutics Special Emphasis Panel

(CERTs SEP), Reviewer

2011 VA QUERI, Rapid Response Project Review Panel, Ad hoc reviewer

2011 VA QUERI, Implementation Service Directed Project Review Panel, Ad hoc reviewer

2011 NIH Neurological, Aging and Musculoskeletal Epidemiology (NAME) Study Section, Ad

hoc reviewer

2011 – 2012 NHLBI Ancillary Studies in Clinical Studies Special Emphasis Panel, Reviewer

2012 VA HSR&D Special CREATE Review, Chair

2013 NCI Special Emphasis Panel, Sensors and Mobile Devices for Health Monitoring SBIR,

Reviewer

2014 – 2015 AHRQ Healthcare Safety and Quality Improvement Research (HSQR) Study Section, Ad

hoc reviewer

Lee TA, Page 39


D. Mentoring

Career Development Awards

Karna Murthy, MD, Children’s Hospital Research Career Development Award, Children’s Hospital. 2008 –

2011.

Min Joo, MD, University of Illinois at Chicago, NHLBI K-23, 1K23HL09446-01A1. 2009 – 2014.

Rahul Khare, MD, Northwestern University, AHRQ K-08, K08HS019005. 2010 – 2015.

Bharati Prasad, MD, University of Illinois at Chicago, University of Chicago/University of Illinois at

Chicago KM1 Career Development, NCI KM-1, KM1CA156717. 2011 – 2013.

Anna Porter, MD, University of Illinois at Chicago, University of Chicago/University of Illinois at Chicago

KM1 Career Development, NCI KM-1, KM1CA156717. 2011 – 2013.

Kaharu Sumino, MD, Washington University, Washington University School of Medicine Clinical Research

Training Center KM1 Comparative Effectiveness Research (CER) Career Development Program. 2012 –

2013.

Visiting Scholars

Piyameth Dilakthornsakul, PharmD, PhD Candidate, Naresuan Univeristy, Thailand. 2012 – 2013.

Fellows

Mehul Soni, PharmD, AstraZeneca Post-Doctoral Fellow, Institute for Health Services Research and Policy

Studies, Northwestern University. 2001 – 2002.

Min Joo, MD, Northwestern University Post-Doctoral T-32 Fellow, Institute for Healthcare Studies,

Northwestern University Feinberg School of Medicine. 2005 – 2007.

Rahul Khare, MD, Northwestern University Post-Doctoral T-32 Fellow, Institute for Healthcare Studies,


Yaojen Chang, PhD, Northwestern University Post-Doctoral T-32 Fellow, Institute for Healthcare Studies,


Rahul Khare, MD, Northwestern University Post-Doctoral F-32 Fellow, Northwestern University Feinberg

School of Medicine. 2009 – 2010.

Patrick Zueger, PharmD, Astellas-UIC Fellow in Pharmacovigilance and Pharmacoepidemiology,

University of Illinois at Chicago, Center for Pharmacoepidemiology and Pharmacoeconomic Research. 2013

– 2015.

Shan Xing, PharmD, NIMH Post-Doctoral F-31 Fellow, College of Pharmacy, University of Illinois at

Chicago. 2017.

Dissertation/Thesis Committees

Student Degree Dissertation/Thesis Title Program Year Role

Zhixaio Wang PhD Medication adherence and

its impact on health care

utilization in veterans with

Type II diabetes


Administration, College

of Pharmacy, University

of Illinois at Chicago

2006 Committee

Member

Lee TA, Page 40



Sarika Ogale PhD Mortality and

cardiovascular outcomes

associated with

medications used in the

treatment of chronic

obstructive pulmonary

disease

Pharmaceutical

Outcomes Research and

Policy Program,

Department of

Pharmacy, University of

Washington

2006 Committee

Member

Caitlyn T. Wilke MS Comparison of utility

weighted and unweighted

HRQL measures: an

empirical study





2007 Committee

Member

Eunmi Jung MS Medication use and

adherence prior to death in

patients with chronic

obstructive pulmonary

disease





2007 Committee

Member

Caitlyn T. Wilke PhD Challenges and

consequences of

medication exposure

definitions in comparative

effectiveness research





2010 Committee

Member

Sruthi

Adimadhyam

MS Risk of arrhythmias

associated with inhaled

anticholinergics in young

individuals with asthma





2011 Committee

Member

Glen T.

Schumock

PhD Association between

leukotriene-modifying

agents and suicide in

patients with asthma

Department of

Epidemiology and

Biostatistics, School of

Public Health, University


2012 Committee

Member

Fang-Ju Lin PhD Condition specific

applications for the

valuation of health


Systems, Outcomes and

Policy, College of


Illinois at Chicago

2013 Committee

Member

Garima Sharma MS Psychometric validation

of the FACIT-dyspnea

scale in COPD patients



Policy, College of


Illinois at Chicago

2013 Committee

Member

Kun Peng MS The misdiagnosis of

COPD by spirometry in

the US



Policy, College of


Illinois at Chicago

2014 Chair

Vardhaman

Patel

PhD Direct thrombin

inhibitors: use and

consequences in patients

with heparin-induced

thrombocytopenia



Policy, College of


Illinois at Chicago

2015 Committee

Member

Lee TA, Page 41



Piyameth

Dilokthornsakul

PhD Pharmacoepidemiology of

medication oversupply

and associated financial

burdens in Thailand

Faculty of

Pharmaceutical Sciences,

Naresuan University

2015 Committee

Member

Matthew

Monberg

PhD Pharmacoepidemiologic

evaluation of

erythropoietin stimulating

agents in head and neck

cancer

Division of

Epidemiology and




2016 Committee

Member

Kibum Kim PhD Insight into the use and

outcomes of anti-platelet

agents in patients with

acute coronary syndrome



Policy, College of


Illinois at Chicago

2016 Committee

Member

Kristin Boulter MPH The association between

topiramate as a

prophylactic migraine

treatment and attention

deficit hyperactivity

disorder in a pediatric

population

Division of

Epidemiology and




2016 Capstone

Committee

Member

Wan-Ju Lee PhD Utilization and risk of

serious infection

associated with TNF-

alpha inhibitors in

children and young adults



Policy, College of


Illinois at Chicago

2016 Committee

Member

Jennifer C.

Samp

PhD Outcomes of patients with

chronic obstructive

pulmonary disease treated

with combination of two

bronchodilators compared

to those treated with

combination long-acting

beta-2 agonist and inhaled

corticosteroid



Policy, College of


Illinois at Chicago

2017 Chair

Shan Xing PhD Impact of second

generation antipsychotics

on diabetes outcomes

among patients with major

depressive disorder and

pre-existing diabetes



Policy, College of


Illinois at Chicago

2017 Chair

Beenish

Manzoor

PhD Navigating safety of oral

anticoagulant use, from

precision medicine to

direct oral anticoagulants:

a mixed-methods

approach



Policy, College of


Illinois at Chicago

2017 Committee

Member

Lee TA, Page 42



Hari Patel Risk evaluation and

prediction of cardiac

events among

azithromycin users



Policy, College of


Illinois at Chicago

In

Progress

Chair

Patrick Zueger Study of trends and

outcomes of prescription

medications ended during

hospice care (STOP

MED)



Policy, College of


Illinois at Chicago

In

Progress

Chair

Deval Gor Antidiabetic drugs in

patients with chronic

kidney disease: trends,

adherence and economic

outcomes



Policy, College of


Illinois at Chicago

In

Progress

Committee

Member

Rachel

Harrington



Policy, College of


Illinois at Chicago

In

Progress

Chair

Ernest Law Department of Pharmacy


Policy, College of


Illinois at Chicago

In

Progress

Committee

Member

Sruthi

Adimadhyam

Comparative safety and

effectiveness of sodium

glucose co-transporter-2

inhibitors in patients with

type 2 diabetes



Policy, College of


Illinois at Chicago

In

Progress

Committee

Member

Inyoung Lee Department of Pharmacy


Policy, College of


Illinois at Chicago

In

Progress

Chair

Graduate Student Dissertation Funding /Awards

Student Award Year(s)

Fang-Ju Lin Dean’s Scholar Fellowship 2012-2013

Wan-Ju Lee Dean’s Scholar Fellowship 2015-2016

Patrick Zueger Dean’s Scholar Fellowship 2016-2017

Patrick Zueger Paul D. Doolen Graduate Scholar for the Study of Aging 2016-2017

Beenish Manzoor Excellence in Research – Best Scientific Poster Award from

ISPE UIC Student Chapter; UIC Research Day

2017

Shan Xing Dean’s Scholar Fellowship 2017-2018

Shan Xing NIMH F31MH114465 2017-2018

Rachel Harrington R25 Cancer Education and Career Development Program

Pre-Doctoral Fellowship

2017-2018

Lee TA, Page 43


E. Community Activities

2006 – 2009 Member, Oak Park Medical Reserve Corps, Oak Park, IL

2009 – 2013 T-ball Coach (boys and girls), Oak Park Youth Baseball / Softball, Oak Park, IL

2010 – 2012 Team Manager, Oak Park River Forest Strikers Soccer Club, Oak Park, IL

2012 – 2014 Team Manager, Chicago Edge Soccer Club, River Forest, IL

2013 – 2016 Boys Youth Basketball Coach, Ascension School, Oak Park, IL

2014 – 2017 Girls Softball Coach, Oak Park Youth Baseball / Softball, Oak Park, IL

2014 – present Board of Directors, Chicago Edge Soccer Club, River Forest, IL

8. ACTIVITY PROFILE

Research and scholarly activity 55%

Instructional activity 20%

University and public service 5%

Student advising / mentoring 10%

Faculty / K-award mentoring 5%

Administration 5%

Documents

Todd A. Lee, PharmD, PhDweb-prod-2.pharm.uic.edu/webdav/toddlee/pci/TODD A... · Curriculum vitae Revised: January 2018 Todd A. Lee, PharmD, PhD 1. GENERAL INFORMATION A. Personal